


AMINE DERIVATIVES

This invention relates to compounds of general formula (1):



- 5 in which A and B have the meanings indicated below, and to processes and intermediates for the preparation of, compositions containing and the uses of such derivatives.

β_2 adrenergic agonists and cholinergic muscarinic antagonists are well-established therapeutic agents for the treatment of obstructive respiratory diseases such as COPD and Asthma.


10 Currently used inhaled β_2 agonists include both short acting agents such as salbutamol (q.i.d.), and terbutaline (t.i.d) and longer acting agents such as salmeterol, and formoterol (b.i.d.) and produce bronchodilation via stimulation of adrenergic receptors on airway smooth muscle.

15 Inhaled Muscarinic antagonists in clinical use include the short acting ipratropium bromide (q.i.d.), oxitropium bromide (q.i.d) and the long acting tiotropium (q.d.). Muscarinic antagonists produce bronchodilation by inhibiting the cholinergic tone of airways primarily by antagonising the action of acetylcholine on muscarinic receptors present on airway smooth muscle. A number of published studies have demonstrated that the combined administration of inhaled β_2 agonists with inhaled muscarinic antagonists (whether short or long acting) to patients with obstructive lung disease results in superior improvements in lung function, symptoms and quality of life


20 measures compared to patients receiving either single class of agent alone. Studies to date have been restricted to combination studies with single pharmacology agents, however combination of both pharmacologies within a single molecule would be desirable as this could yield increased bronchodilator efficacy with similar therapeutic index to the single agents or similar efficacy with superior therapeutic index. In addition, combining both pharmacologies in a

25 single molecule would allow the potential for combination with anti-inflammatory agents thus giving a triple therapy from a single inhaler.

The invention relates to the compounds of general formula (1):



- 30 wherein A is selected from:




and

wherein * represent the attachment point of A to the carbon bearing the hydroxy;
and B is selected from:

- 5 1) $^{**}-(CH_2)_2-(CH_2)_m-X^1-(CH_2)_n-^{***}$ wherein X^1 is O or S, m is an integer from 0 to 9, n is an integer from 0 to 9 and n+m is comprised between 4 to 9 inclusive;

2) C_6-C_{12} alkylene optionally substituted with one or two C_1-C_4 alkyl;


- 10 3) a group of formula



wherein X^2 is O or S, r is an integer from 2 to 7, s is an integer from 0 to 6, t is an integer from 0 to 6, s+t is comprised between 1 to 6 inclusive and r+s+t is comprised between 3 to 8 inclusive;
and

15

- 4) a group of formula



- 20 ** representing the attachment point of B to the adjacent NH group and *** representing the attachment point of B to the adjacent phenyl group;


and quaternary ammonium salts thereof or, if appropriate, their pharmaceutically acceptable salts and/or isomers, tautomers, solvates or isotopic variations thereof.

- 25 The compounds of formula (1) are β_2 adrenergic receptor agonists and muscarinic receptor antagonists that are particularly useful for the treatment of diseases and/or conditions involving

said receptors, by showing excellent potency, in particular when administered via the inhalation route.

The compounds of the formula (1)

5




(1)

can be prepared using conventional procedures such as by the following illustrative methods in which A and B are as previously defined for the compounds of the formula (1) unless otherwise stated.

10


The amine derivative of the formula (1) may be prepared by reaction of an amine of formula (2):



(2)

wherein Ra represents hydrogen or a suitable hydroxy-protecting group, preferably benzyl, with a bromide of formula (3):

15



(3)

wherein A is as defined above for the compounds of formula (1). Preferably the hydroxy groups of A are protected with suitable hydroxyl protecting groups. A preferred hydroxyl protecting group is benzyl.

20


In a typical procedure, the amine of formula (2) is reacted with a bromide of formula (3) optionally in the presence of a solvent or mixture of solvents (e.g. dimethyl sulphoxide, toluene, *N,N*-dimethylformamide, propionitrile, acetonitrile), optionally in the presence of a suitable base (e.g. triethylamine, diisopropylethylamine, potassium carbonate, potassium hydrogen carbonate, sodium hydrogen carbonate) at a temperature comprised between 80°C and 120°C, for 12 to 48

25

hours. The protecting groups can then be removed using standard methodology for cleaving oxygen protecting groups such as those found in the text book T. W. Greene, Protective Groups in Organic Synthesis, A. Wiley-Interscience Publication, 1981.

- 5 The bromides of formula (3) may be prepared according to the methods of WO2005/080324, US2005/222128, WO2004/032921, US2005/215590, WO2005/092861.

The amine of formula (2) may be prepared from the corresponding protected amine of formula (4):




(4)

10


wherein R_b and R_c represent any suitable substituents so that the bonds between the N atom and R_b and the N atom and R_c may be easily cleaved to give the free amine of formula (2) using standard methodology for cleaving nitrogen protecting groups such as those found in the text book T. W. Greene, Protective Groups in Organic Synthesis, A. Wiley-Interscience Publication, 1981. For example R_b and R_c could be selected from allyl, benzyl, t-butyl carbamate or when

15 joined together to form phthalimide. Preferably R_b and R_c are both tertbutyl carbamate or R_b is H and R_c is tertbutyl carbamate.

- The amine of formula (4), wherein R_a is benzyl and B is selected from $(CH_2)_2-(CH_2)_m-X^1-(CH_2)_n$ where n is 0 and m and X^1 are as defined for compounds of formula (1) or a group of formula
- 20




wherein t is 0 and r, s and X^2 are as defined for compounds of formula (1); may be prepared by reaction of a compound of formula (5):




(5)

wherein X^3 is O or S, with a compound of formula (6):



wherein B^1 is $(\text{CH}_2)_2-(\text{CH}_2)_m$ or a group of formula:



5

In a typical procedure, the alcohol compound of formula (6) is first converted to a halide (e.g. bromide, chloride, iodide) or sulphonate (e.g. mesylate) using standard procedures (e.g. triphenylphosphine/iodine; triphenylphosphine/carbon tetrabromide; thionyl chloride; methanesulphonyl chloride/triethylamine) in the presence of a solvent or mixture of solvents (e.g. dimethyl sulfoxide, dichloromethane, toluene, *N,N*-dimethylformamide, propionitrile, acetonitrile). This product is then reacted with the compound of formula (5) in the presence of a solvent or mixture of solvents (e.g. dimethyl sulfoxide, toluene, *N,N*-dimethylformamide, acetonitrile, tetrahydrofuran) optionally in the presence of a suitable base (e.g. triethylamine, diisopropylethylamine, potassium carbonate, potassium hydrogen carbonate, sodium hydrogen carbonate) at a temperature comprised between 60°C and 120°C, for 4 to 48 hours.


10

15

Alternatively, a Mitsunobu protocol may be employed (e.g. diethyl azodicarboxylate/triphenylphosphine) in the presence of a solvent or mixture of solvents (e.g. toluene, acetonitrile, tetrahydrofuran) at a temperature comprised between 25°C and 60°C, for 2 to 4 hours.

20

The compound of formula (5) wherein X^3 is O may be prepared from the aldehyde of formula (7):




(7)

25

In a typical procedure, the aldehyde (7) is treated with an oxidant (e.g. hydrogen peroxide; meta-chloroperbenzoic acid) in the presence of a solvent or mixture of solvents (e.g. methanol, water, acetonitrile), in the presence of an acid (e.g. sulphuric acid) at a temperature comprised between 25°C and 60°C, for 6 to 24 hours.

The aldehyde of formula (7) may be prepared according to the method of WO 2005/012227.

The compound of formula (5) wherein X^3 is S may be prepared from an halide of formula (13):



5

(13)

In a typical procedure, the said halide (13) is reacted with triisopropylsilanethiol in the presence of a suitable palladium catalyst (e.g. palladium acetate/ tri-*ortho*-tolylphosphine of formula $\text{Pd}(\text{OAc})_2/\{\text{P}(\text{o-Tol})_3\}_2$) in the presence of a solvent or mixture of solvents (e.g. toluene, acetonitrile, hexane) in the presence of a base (e.g. triethylamine, diisopropylethylamine, potassium carbonate, sodium hydrogen carbonate). Preferably, the reaction is carried out at a temperature comprising between 70°C and 110°C for 4 to 16 hours. The product silyl thioether is then deprotected using the methods found in the textbook T. W. Greene, Protective Groups in Organic Synthesis, A. Wiley-Interscience Publication, 1981.

15

The aryl bromide of formula (13) may be prepared according to the method of WO 1994/11337.

The alcohol compound of formula (6) may be prepared from commercial amines using the methods found in the textbook T. W. Greene, Protective Groups in Organic Synthesis, A. Wiley-Interscience Publication, 1981.


20

The amine of formula (4), wherein B is selected from

- $(\text{CH}_2)_2-(\text{CH}_2)_m-X^1-(\text{CH}_2)_n$ wherein X^1 is O or S, m is an integer from 0 to 9, n is an integer from 3 to 9 and $n+m$ is comprised between 4 to 9;


25 - $\text{C}_6\text{-C}_{12}$ alkylene optionally substituted with one or two $\text{C}_1\text{-C}_4$ alkyl;

- a group of formula:



wherein X^2 is O or S, r is an integer from 2 to 7, s is an integer 0 to 6 and t is an integer from 3 to 6 and $s+t$ is comprised between 3 to 6 and $r+s+t$ is comprised between 5 to 8,

30 may be prepared from the amine of formula (8):




(8)

wherein B^2 is $-CH_2-(CH_2)_m-X^1-(CH_2)_{n1}$ wherein X^1 is O or S, m is an integer from 0 to 9, n_1 is an integer from 1 to 7 and n_1+m is comprised between 2 to 7;


- C_3 - C_9 alkylene optionally substituted with one or two C_1 - C_4 alkyl;

5 - a group of formula



wherein X^2 is O or S, r_1 is an integer from 1 to 6, s is an integer 0 to 6 and t_1 is an integer from 1 to 4 and $s+t_1$ is comprised between 1 to 4 and r_1+s+t_1 is comprised between 2 to 5.


- 10 In a typical procedure, the amine of formula (8) is treated to hydrogenation using a metal catalyst (e.g. palladium on carbon; platinum oxide) in the presence of a solvent (e.g. methanol, ethanol, ethyl acetate, tetrahydrofuran) with a hydrogen source (e.g. ammonium formate; formic acid, hydrogen) at a temperature comprised between 20°C and 90°C, for 1 to 6 hours.
- 15 The amine of formula (8) may be prepared from reaction of the aldehyde of formula (7) as previously described with a phosphonium salt of formula (9):



(9).

- 20 In a typical procedure, the phosphonium salt (9) treated with a suitable base (e.g. sodium hydride, triethylamine, *n*-butyl lithium, hexamethyldisilazide) then reacted with the aldehyde (8) in the presence of a solvent or mixture of solvents (e.g. toluene, tetrahydrofuran, acetonitrile). Preferably, the reaction is carried out at a temperature comprised between 50°C and 110°C for 4 to 24 hours.

- 25 The phosphonium salt (9) may be prepared by reaction of triphenyl phosphine with the bromide of formula (10):




In a typical procedure the bromide of formula (10) is reacted with triphenyl phosphine, optionally in the presence of a solvent or mixture of solvents (e.g. toluene, tetrahydrofuran, acetonitrile).

- 5 Preferably, the reaction is carried out at a temperature comprised between 50°C and 110°C for 1 to 5 days.

The bromide of formula (10) may be formed by the reaction of a suitable amine or amine equivalent with a dibromide of formula (11):


10



In a typical procedure, the dibromide of formula (11) is reacted with a suitable amine or amine equivalent (e.g. phthalimide, di-*tert*-butyl iminodicarbamate) in the presence of a solvent or mixture of solvents (e.g. toluene, tetrahydrofuran, acetonitrile) and with a suitable base (e.g. sodium hydride, triethylamine, *n*-butyl lithium). Preferably, the reaction is carried out at a temperature comprised between 25°C and 110°C for 4 to 24 hours.

15

The dibromide (11) may either be commercial or formed from a dialcohol of formula (12):



using standard methods (e.g. triphenylphosphine/carbon tetrabromide), in the presence of a solvent or mixture of solvents (e.g. dichloromethane, toluene, *N,N*-dimethylformamide, propionitrile, acetonitrile).

20

Compounds of formula (12) are commercially available or can be easily prepared by a man skilled in the art using commercially available materials and standard methods.


25

Alternatively the amine of formula (4), wherein B is selected from:


- $(\text{CH}_2)_2 \text{---} (\text{CH}_2)_m \text{---} \text{X}^1 \text{---} (\text{CH}_2)_n$ wherein X^1 is O or S, m is an integer from 0 to 9, n is an integer from 3 to 9 and $n+m$ is comprised between 4 to 9;

- $\text{C}_6 \text{---} \text{C}_{12}$ alkylene optionally substituted with one or two $\text{C}_1 \text{---} \text{C}_4$ alkyl;


- 30 - or a group of formula:



wherein X^2 is O or S, r is an integer from 2 to 7, s is an integer 0 to 6 and t is an integer from 3 to 6 and $s+t$ is comprised between 3 to 6 inclusive and $r+s+t$ is comprised between 5 to 8 inclusive, may be prepared by reaction of the bromide of formula (13):



with the alkene of formula (14):




wherein B² is as defined above.

5

In a typical procedure, the aryl halide of formula (13) is reacted with the alkene of formula (14) in the presence of a suitable palladium catalyst (e.g. palladium acetate/ tri-*ortho*-tolylphosphine of formula Pd(OAc)₂/P(o-Tol)₃)₂) in the presence of a solvent or mixture of solvents (e.g. toluene, acetonitrile, hexane) in the presence of a base (e.g. triethylamine, diisopropylethylamine, potassium carbonate, potassium hydrogen carbonate). Preferably, the reaction is carried out at a temperature comprising between 70°C and 110°C for 4 to 16 hours.

10

The aryl bromide of formula (13) may be prepared according to the method of WO 1994/11337. The amine of formula (14) may be prepared from commercial halides of formula (15):




15


wherein X is Cl, Br or I. In a typical procedure the halide (15) is reacted with a suitable amine or amine equivalent (e.g. phthalimide, di-*tert*-butyl iminodicarbamate) in the presence of a solvent or mixture of solvents (e.g. toluene, tetrahydrofuran, acetonitrile) and with a suitable base (e.g. sodium hydride, triethylamine, *n*-butyl lithium). Preferably, the reaction is carried out at a temperature comprised between 25°C and 110°C for 4 to 24 hours.

20


Alternatively if amine (14) is of the formula (16):



wherein X² is O or S and t₂ is an integer from 1 to 4, then this may be formed by reaction of a compound of formula (17):



with commercial halides of formula (18):



wherein X is Cl, Br or I.


5

In a typical procedure the compound of formula (17) is treated with the halide (18) in the presence of a solvent or mixture of solvents (e.g. dimethyl sulphoxide, toluene, *N,N*-dimethylformamide, acetonitrile, tetrahydrofuran), optionally in the presence of a suitable base (e.g. triethylamine, diisopropylethylamine, potassium carbonate, potassium hydrogen carbonate, sodium hydride) at a temperature comprised between 0°C and 80°C, for 1 to 48 hours.

10

Compounds of formula (17) where X² is O may be prepared from commercial 3-(2-aminoethyl)phenol or 4-(2-aminoethyl)phenol using the methods found in the textbook T. W. Greene, *Protective Groups in Organic Synthesis*, A. Wiley-Interscience Publication, 1981.

15 Compounds of formula (17) where X² is S may be formed from a halide of formula (17a):




wherein X is Cl, Br or I.

20 In a typical procedure, the said halide (17a) is reacted with triisopropylsilanethiol in the presence of a suitable palladium catalyst (e.g. palladium acetate/ tri-*ortho*-tolylphosphine of formula Pd(OAc)₂/[P(*o*-Tol)₃]₂) in the presence of a solvent or mixture of solvents (e.g. toluene, acetonitrile, hexane) in the presence of a base (e.g. triethylamine, diisopropylethylamine, potassium carbonate, sodium hydrogen carbonate). Preferably, the reaction is carried out at a temperature comprising between 70°C and 110°C for 4 to 16 hours. The product silyl thioether is


25 then deprotected using the methods found in the textbook T. W. Greene, *Protective Groups in Organic Synthesis*, A. Wiley-Interscience Publication, 1981.

The halides of formula (17a) may be prepared from commercial halides of formula (17b):




using the methods found in the textbook T. W. Greene, *Protective Groups in Organic Synthesis*, A. Wiley-Interscience Publication, 1981.

Alternatively if the amine (4) is of the formula (19):



5


then it may be formed by reaction of a compound of formula (17) with a compound of formula (20):



In a typical procedure, the compound of formula (20) is first converted to a halide (e.g. bromide, chloride, iodide) or sulphonate (e.g. mesylate) using standard procedures (e.g. triphenylphosphine/iodine; triphenylphosphine/carbon tetrabromide; thionyl chloride; methanesulphonyl chloride/triethylamine) in the presence of a solvent or mixture of solvents (e.g. dimethyl sulphoxide, dichloromethane, toluene, *N,N*-dimethylformamide, propionitrile, acetonitrile). This product is then reacted with the compound of formula (17) in the presence of a solvent or mixture of solvents (e.g. dimethyl sulphoxide, toluene, *N,N*-dimethylformamide, acetonitrile, tetrahydrofuran) optionally in the presence of a suitable base (e.g. triethylamine, diisopropylethylamine, potassium carbonate, potassium hydrogen carbonate) at a temperature comprised between 60°C and 120°C, for 4 to 48 hours.

Alternatively, a Mitsunobu protocol may be employed (e.g. diethyl azodicarboxylate/triphenylphosphine) in the presence of a solvent or mixture of solvents (e.g. toluene, acetonitrile, tetrahydrofuran) at a temperature comprised between 25°C and 60°C, for 2 to 4 hours.


The compound of formula (20) can be formed from an alkene of formula (21):



(21)

- by reaction with a boronating agent (e.g. borane, 9-Borabicyclo[3.3.1]nonane) in the presence of a suitable solvent (e.g. tetrahydrofuran) at a temperature comprising between 60°C and 100°C for 4 to 24 hours. Followed by oxidation with hydrogen peroxide in a suitable solvent or mixture of solvents (e.g. water, methanol, tetrahydrofuran) with a suitable base (e.g. sodium hydroxide).
- The alkene of formula (21) may be formed from the aryl bromide (13) by reaction with a suitable vinyl compound (e.g. vinyltributylstannane; potassium vinyltetrafluoroborate; 2,4,6-trivinylcycloboroxane pyridine complex). In a typical procedure, the aryl halide (13) and the vinyl compound are reacted in the presence of a suitable palladium catalyst (e.g. palladium acetate/ tri-*ortho*-tolylphosphine of formula $\text{Pd}(\text{OAc})_2/\{\text{P}(\text{o-Tol})_3\}_2$) in the presence of a solvent or mixture of solvents (e.g. toluene, acetonitrile, hexane), in the presence of a base (e.g. triethylamine, diisopropylethylamine, potassium carbonate, potassium hydrogen carbonate). Preferably, the reaction is carried out at a temperature comprised between 70°C and 110°C for 4 to 16 hours.

- Alternatively, the compound of formula (20) can be formed from an ester of formula (37):




(37)

- by reaction with a reducing agent (e.g. lithium aluminium hydride, lithium borohydride) in the presence of a suitable solvent (e.g. tetrahydrofuran) at a temperature comprising between 0°C and 100°C for 4 to 24 hours.
- The ester of formula (37) may be formed from the aryl bromide of formula (13) as here before described by reaction with an anion of tert-butylacetate under palladium catalysis. In a typical procedure, the aryl halide (13) and the ester anion are reacted in the presence of a suitable palladium catalyst (e.g. palladium dibenzylidene acetate or palladium acetate/ tri-*ortho*-tolylphosphine of formula $\text{Pd}(\text{OAc})_2/\{\text{P}(\text{o-Tol})_3\}_2$) in the presence of a solvent or mixture of solvents (e.g. toluene, acetonitrile, hexane), in the presence of a base (e.g. triethylamine, diisopropylethylamine, potassium carbonate, potassium hydrogen carbonate, lithium

hexamethyldisilazide). Preferably, the reaction is carried out at a temperature comprised between 0°C and 110°C for 4 to 16 hours.

Alternatively, the amine of formula (2) may be prepared from the corresponding nitrile of formula


5 (22):



wherein B² is as defined above.

10 In a typical procedure, the nitrile of formula (22) is treated to hydrogenation using a metal catalyst or combination of catalysts (e.g. palladium on carbon; platinum oxide, Raney-Nickel®) in the presence of a solvent (e.g. methanol, ethanol, ethyl acetate, tetrahydrofuran) with a hydrogen source (e.g. ammonium formate, formic acid, hydrogen) at a temperature comprised between 20°C and 90°C, for 1 to 6 hours.


15 The nitrile of formula (22) may be prepared by reaction of the aryl bromide (13) with an alkene of formula (23):



20 In a typical procedure, the aryl halide of formula (13) is reacted with the alkene of formula (14) in the presence of a suitable palladium catalyst (e.g. palladium acetate/ tri-*ortho*-tolylphosphine of formula Pd(OAc)₂/P(o-Tol)₃)₂) in the presence of a solvent or mixture of solvents (e.g. toluene, acetonitrile, hexane) in the presence of a base (e.g. triethylamine, diisopropylethylamine, potassium carbonate, potassium hydrogen carbonate). Preferably, the reaction is carried out at a temperature comprising between 70°C and 110°C for 4 to 16 hours.

25 The alkene of formula (23) may be commercial.


Alternatively, if alkene (23) is of formula (24) as follows:



wherein X³ is O or S,

30 B⁴ is CH₂-(CH₂)_m wherein m is an integer from 0 to 9 and B⁵ is (CH₂)_{n1} wherein n₁ is an integer from 1 to 7, and n₁+m is comprised between 2 to 7 inclusive, or,


B⁴ is a group of formula:




wherein r₁ is an integer from 1 to 6, s is an integer 0 to 6, and B⁵ is a group (CH₂)_{t1} wherein t₁ is an integer from 1 to 4, and s+t₁ is comprised between 1 to 4 inclusive and r₁+s+t₁ is comprised

5 between 2 to 5 inclusive;

then said compound of formula (24) can be formed by reaction of a compound of formula (25):



with a compound of formula (26):



10


In a typical procedure, one of the compound (25) or (26) is first converted to a halide (e.g. bromide, chloride, iodide) or sulphonate (e.g. mesylate) using standard procedures (e.g. triphenylphosphine/iodine; triphenylphosphine/carbon tetrabromide; thionyl chloride; methanesulphonyl chloride/triethylamine) in the presence of a solvent or mixture of solvents (e.g. dimethyl sulfoxide, dichloromethane, toluene, N,N-dimethylformamide, propionitrile, acetonitrile). This product is then reacted with the other compound (26) or (25) in the presence of a solvent or mixture of solvents (e.g. water, dimethyl sulfoxide, toluene, N,N-dimethylformamide, acetonitrile, tetrahydrofuran, dichloromethane) in the presence of a suitable base (e.g. sodium hydroxide, potassium tert-butoxide, sodium hydride) optionally in the presence of a phase transfer catalyst (e.g. tetra-ethylammonium bromide) at a temperature comprised between 25°C and 120°C, for 4 to 48 hours.

20

Compounds of formula (25) and (26) are commercially available or can easily be prepared using well-known procedures.

25

Alternatively, the amine of formula (2) may be prepared from the corresponding nitrile of formula (32):




(32)

wherein B² is as defined above.

In a typical procedure, the nitrile of formula (32) is treated to hydrogenation using a metal catalyst or combination of catalysts (e.g. palladium on carbon; platinum oxide, Raney-Nickel[®]) in the presence of a solvent (e.g. methanol, ethanol, ethyl acetate, tetrahydrofuran) with a hydrogen source (e.g. ammonium formate, formic acid, hydrogen) at a temperature comprised
 5 between 20°C and 90°C, for 1 to 6 hours.

The nitrile of formula (32) may be prepared by reaction of the aryl bromide (13) with an alkyne of formula (33):




10

In a typical procedure, the aryl halide of formula (13) is reacted with the alkyne of formula (33) in the presence of a suitable palladium catalyst (e.g. palladium tetrakis(triphenylphosphine) or palladium acetate/ tri-*ortho*-tolylphosphine of formula Pd(OAc)₂{P(*o*-Tol)₃}₂) in the presence of a solvent or mixture of solvents (e.g. toluene, acetonitrile, hexane) in the presence of a base (e.g.
 15 triethylamine, piperidine, diisopropylethylamine, potassium carbonate, potassium hydrogen carbonate). Preferably, the reaction is carried out at a temperature comprising between 70°C and 110°C for 4 to 16 hours.

The alkyne of formula (33) may be commercial.

20

Alternatively, if alkyne (33) is of formula (34) as follows:




wherein X³ is O or S,

B⁴ is CH₂-(CH₂)_m wherein m is an integer from 0 to 9 and B⁵ is (CH₂)_{n1} wherein n₁ is an integer

25 from 1 to 7, and n₁+m is comprised between 2 to 7 inclusive, or,


B⁴ is a group of formula:




wherein r₁ is an integer from 1 to 6, s is an integer 0 to 6, and B⁵ is a group (CH₂)_{t1} wherein t₁ is an integer from 1 to 4, and s+t₁ is comprised between 1 to 4 inclusive and r₁+s+t₁ is comprised

30 between 2 to 5 inclusive;

then said compound of formula (34) can be formed by reaction of a compound of formula (25):




with a compound of formula (36):




- In a typical procedure, one of the compound (35) or (36) is first converted to a halide (e.g. bromide, chloride, iodide) or sulphonate (e.g. mesylate) using standard procedures (e.g. triphenylphosphine/iodine; triphenylphosphine/carbon tetrabromide; thionyl chloride; methanesulphonyl chloride/triethylamine) in the presence of a solvent or mixture of solvents (e.g. dimethyl sulfoxide, dichloromethane, toluene, N,N-dimethylformamide, propionitrile, acetonitrile). This product is then reacted with the other compound (36) or (35) in the presence of a solvent or mixture of solvents (e.g. water, dimethyl sulfoxide, toluene, N,N-dimethylformamide, acetonitrile, tetrahydrofuran, dichloromethane) in the presence of a suitable base (e.g. sodium hydroxide, potassium tert-butoxide, sodium hydride) optionally in the presence of a phase transfer catalyst (e.g. tetra-ethylammonium bromide) at a temperature comprised between 25°C and 120°C, for 4 to 48 hours.
- The compounds of formula (35) and (36) are commercially available or are easily prepared according to well known processes.

The compounds of formula (1) wherein B is selected from $(\text{CH}_2)_2-(\text{CH}_2)_m-\text{X}^1-(\text{CH}_2)_n$ where n is 1 or a group of formula



wherein t is 1, may be prepared by reaction of an amine of formula (27):




(27)

wherein X^3 , B^1 and Ra are as defined above, with a bromide of formula (3).

- In a typical procedure, the amine of formula (27) is reacted with a bromide of formula (3) optionally in the presence of a solvent or mixture of solvents (e.g. dimethyl sulfoxide, toluene, N,N-dimethylformamide, propionitrile, acetonitrile), optionally in the presence of a suitable base (e.g. triethylamine, diisopropylethylamine, potassium carbonate, sodium hydrogen carbonate) at a temperature comprised between 80°C and 120°C, for 12 to 48 hours. The protecting groups can then be removed using standard methodology for cleaving oxygen protecting groups such


as those found in the text book T. W. Greene, *Protective Groups in Organic Synthesis*, A. Wiley-Interscience Publication, 1981.

The amine of formula (27) may be prepared from the corresponding protected amine of formula (28):




wherein Rb and Rc are as defined above.

The amine (28) may be prepared by reaction of alcohol (29):



with a compound of formula (30):




In a typical procedure, the alcohol of formula (29) is first converted to a halide (e.g. bromide, chloride, iodide) or sulphonate (e.g. mesylate) using standard procedures (e.g. triphenylphosphine/iodine; triphenylphosphine/carbon tetrabromide; thionyl chloride; methanesulphonyl chloride/triethylamine) in the presence of a solvent or mixture of solvents (e.g. dimethyl sulfoxide, dichloromethane, toluene, *N,N*-dimethylformamide, propionitrile, acetonitrile). This product is then reacted with the compound of formula (30) in the presence of a solvent or mixture of solvents (e.g. water, dimethyl sulfoxide, toluene, *N,N*-dimethylformamide, acetonitrile, tetrahydrofuran, dichloromethane) in the presence of a suitable base (e.g. sodium hydroxide, potassium *tert*-butoxide, sodium hydride) optionally in the presence of a phase transfer catalyst (e.g. tetra-ethylammonium bromide) at a temperature comprised between 25°C and 120°C, for 4 to 48 hours.

The alcohol of formula (29) may be prepared from the aldehyde of formula (7). In a typical procedure the aldehyde (7) is treated with a reductant (e.g. sodium borohydride; lithium aluminium hydride) in the presence of a solvent (e.g. tetrahydrofuran, methanol, toluene) at a temperature comprising between 0°C and 40°C, for 1 to 24 hours.

5


The compound of formula (30) may be prepared from commercial alcohol of formula (31):




using the methods found in the textbook T. W. Greene, Protective Groups in Organic Synthesis, A. Wiley-Interscience Publication, 1981.

10


Finally, if the amine (4) is of the formula (38) as follows:



then it may be formed by reaction of a compound of formula (39):



15 with a compound of formula (20):



Above compounds of formula (39) may be prepared according to the methods described in WO97/34905.


20

In a typical procedure, the compound of formula (20) is first converted to a halide (e.g. bromide, chloride, iodide) or sulphonate (e.g. mesylate) using standard procedures (e.g. triphenylphosphine/iodine; triphenylphosphine/carbon tetrabromide; thionyl chloride; methanesulphonyl chloride/triethylamine) in the presence of a solvent or mixture of solvents (e.g.

dimethyl sulphoxide, dichloromethane, toluene, *N,N*-dimethylformamide, propionitrile, acetonitrile). This product is then reacted with the compound of formula (39) in the presence of a solvent or mixture of solvents (e.g. dimethyl sulphoxide, toluene, *N,N*-dimethylformamide, acetonitrile, tetrahydrofuran) optionally in the presence of a suitable base (e.g. triethylamine, diisopropylethylamine, potassium carbonate, potassium hydrogen carbonate) at a temperature comprised between 60°C and 120°C, for 4 to 48 hours.

Alternatively, a Mitsunobu protocol may be employed (e.g. diethyl azodicarboxylate/triphenylphosphine) in the presence of a solvent or mixture of solvents (e.g. toluene, acetonitrile, tetrahydrofuran) at a temperature comprised between 25°C and 60°C, for 2 to 4 hours.

The quaternary ammonium salts of compounds of the formula (1) include compounds of formula



wherein R^1 is selected from H, C_1 - C_4 alkyl, benzyl or phenethyl and X^- is a suitable counter ion such as acetate, mesylate, xinafoate, tartrate, chloride, bromide, iodide, sulphate, phosphate(s), nitrate, citrate, methanesulfonate, carboxylate with from 1 to 6 carbon atoms, dicarboxylate with from 2 to 6 carbon atoms, maleate, fumarate and benzoate. For other acceptable quaternary ammonium salts, see Int. J. Pharm, 33, 201-217 (1986). Preferably X is acetate, fumarate, mesylate, bromide, chloride, sulphate, D and L tartrate or xinafoate. Said quaternary ammonium salts may be prepared by reacting a compound of formula (4) with an alkylating agent R^1-X wherein R^1 is a C_1 - C_4 alkyl, benzyl or phenethyl and X is a suitable leaving group (a preferred R^1-X groups is methyl iodide) in the presence of a solvent or mixture of solvents (e.g. dimethyl sulphoxide, toluene, *N,N*-dimethylformamide, propionitrile, acetonitrile, dichloromethane) optionally in the presence of a suitable base (e.g. triethylamine, diisopropylethylamine, potassium carbonate, potassium hydrogen carbonate) at a temperature comprised between 60°C and 120°C, for 4 to 48 hours. The resulting quaternary ammonium salt of compound of formula (4) is then deprotected and reacted with a bromide of formula (3) as disclosed above, in order to obtain said quaternary ammonium salt of compound of formula (1).

For some of the steps of the here above described process of preparation of the compounds of formula (1), it may be necessary to protect potential reactive functions that are not wished to react, and to cleave said protecting groups in consequence. In such a case, any compatible protecting radical can be used. In particular methods of protection and deprotection such as

those described by T.W. GREENE (*Protective Groups in Organic Synthesis*, A. Wiley-Interscience Publication, 1981) or by P. J. Kocienski (*Protecting groups*, Georg Thieme Verlag, 1994), can be used.

- 5 All of the above reactions and the preparations of novel starting materials used in the preceding methods are conventional and appropriate reagents and reaction conditions for their performance or preparation as well as procedures for isolating the desired products will be well-known to those skilled in the art with reference to literature precedents and the examples and preparations hereto.

10


Also, the compounds of formula (1) as well as intermediate for the preparation thereof can be purified according to various well-known methods, such as for example crystallization or chromatography.

- 15 Preferred definitions of B are as indicated here below.


According to one embodiment, $(\text{CH}_2)_8$, $(\text{CH}_2)_9$ and $(\text{CH}_2)_{10}$ are preferred when B is a C_6 - C_{12} alkylene optionally substituted with one or two C_1 - C_4 alkyl.

- 20 According to another embodiment $-(\text{CH}_2)_6\text{-O-}(\text{CH}_2)_3$, $-(\text{CH}_2)_6\text{-O-}(\text{CH}_2)_4$, and $-(\text{CH}_2)_7\text{-O-}$ are preferred when B is of formula $**-(\text{CH}_2)_2-(\text{CH}_2)_m\text{-X}^1-(\text{CH}_2)_n-***$.

According to another embodiment, when B is of formula:




- 25 then the following are preferred:



Preferably, the oxygen is in the meta or para position. More preferably the oxygen is in the para position.


30

According to another embodiment, when B is of formula:




Then the oxygen in the para position is preferred.

- Quaternary ammonium salts of compounds of formula (1) are also preferred. Preferred
 5 quaternary ammonium salts are:




wherein X is acetate, fumarate, mesylate, bromide, chloride, sulphate, D and L tartrate or xinafoate.

- 10 According to another embodiment of the present invention, the quaternary ammonium salts of formula:




wherein X is succinate are also preferred.

- 15 Preferably A is a group of formula:



More preferably, A is a group of formula:



Particularly preferred compounds according to the invention are:

- N-5-[(1R)-2-[(10-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}decyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl)methanesulfonamide;
- 5 N-5-[(1R)-2-[(2-{4-(3-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}propoxy)phenyl}ethyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl)methanesulfonamide;
- N-5-[(1R)-2-[(2-{4-(4-{3-[(1R)-3-(Diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)phenyl}ethyl)amino)-1-hydroxyethyl]-2-hydroxyphenyl)methanesulfonamide;
- 10 N-5-[(1R)-2-[(7-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenoxy}heptyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl)methanesulfonamide;
- N-5-[(1R)-2-[(2-{4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}ethoxy)phenyl}ethyl)amino)-1-hydroxyethyl]-2-hydroxyphenyl)methanesulfonamide;
- 15 N-5-[(1R)-2-[(6-{4-(3-[(1R)-3-(Diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)hexyl)amino)-1-hydroxyethyl]-2-hydroxyphenyl)methanesulfonamide;
- N-5-[(1R)-2-[(2-{4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)phenyl}ethyl)amino)-1-hydroxyethyl]-2-hydroxyphenyl]formamide;
- 5-[(1R)-2-[(2-{4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)phenyl}ethyl)amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one;
- 20 5-[(1R)-1-[(hydroxy)-2-[(2-{4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)phenyl}ethyl)amino)ethyl]benzene-1,3-diol;
- N-5-[(1R)-2-[(2-{3-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}ethoxy)phenyl}ethyl)amino)-1-hydroxyethyl]-2-hydroxyphenyl)methanesulfonamide;
- 25 2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-(2-{3-[2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)ethyl]phenoxy}ethyl)phenol;
- 5-[(1R)-2-[(2-{4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}ethoxy)phenyl}ethyl)amino)-1-hydroxyethyl]benzene-1,3-diol;
- N-5-[(1R)-2-[(2-{4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}ethoxy)phenyl}ethyl)amino)-1-hydroxyethyl]-2-hydroxyphenyl]formamide;
- 30 5-[(1R)-2-[(2-{4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}ethoxy)phenyl}ethyl)amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one;
- 2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-(2-{4-[2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)ethyl]phenoxy}ethyl)phenol;

- N-{5-[(1R)-2-[(8-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}octyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide;
- N-{5-[(1R)-2-[(2-{4-[(5-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}pentyl)oxy]phenyl}ethyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide;
- 5 2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-{4-[2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)ethyl]phenoxy}butyl}phenol;
- N-{5-[(1R)-2-[(2-{4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}ethoxy)phenyl}ethyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide succinate salt; and
- 5-[(1R)-2-[(2-{4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}ethoxy)phenyl]
- 10 -11-dimethylethyl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one,
- or, if appropriate, their pharmaceutically acceptable salts and/or isomers, tautomers, solvates or isotopic variations thereof.

Most preferred compounds according to the invention are:

- 15 N-{5-[(1R)-2-[(2-{4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}ethoxy)phenyl}ethyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide;
- N-{5-[(1R)-2-[(6-{4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)hexyl]amino]-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide;
- 5-[(1R)-2-[(2-{4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)phenyl}ethyl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one;
- 20 N-{5-[(1R)-2-[(2-{4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}ethoxy)phenyl}ethyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl}formamide;
- 5-[(1R)-2-[(2-{4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}ethoxy)phenyl}ethyl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one;
- 25 N-{5-[(1R)-2-[(2-{4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}ethoxy)phenyl}ethyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide succinate salt; and
- 5-[(1R)-2-[(2-{4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}ethoxy)phenyl]
- 11-dimethylethyl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one;
- or, if appropriate, their pharmaceutically acceptable salts and/or isomers, tautomers, solvates or
- 30 isotopic variations thereof.

Pharmaceutically acceptable salts of the compounds of formula (1) and quaternary ammonium salt thereof include the acid addition and base salts thereof.

- 35 Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate,

naphthylate, 1,5-naphthalenedisulfonate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, saccharate, stearate, succinate, tartrate, tosylate and trifluoroacetate salts.

- 5 Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts. Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.

10

For a review on suitable salts, see "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).

- Pharmaceutically acceptable salts of compounds of formula (1) and quaternary ammonium salt thereof may be prepared by one or more of three methods:

- 15 (i) by reacting the compound of formula (1) with the desired acid or base;
(ii) by removing an acid- or base-labile protecting group from a suitable precursor of the compound of formula (1) or by ring-opening a suitable cyclic precursor, for example, a lactone or lactam, using the desired acid or base; or
20 (iii) by converting one salt of the compound of formula (1) to another by reaction with an appropriate acid or base or by means of a suitable ion exchange column.

- All three reactions are typically carried out in solution. The resulting salt may precipitate out and be collected by filtration or may be recovered by evaporation of the solvent. The degree of
25 ionisation in the resulting salt may vary from completely ionised to almost non-ionised.

- The compounds of the invention may exist in both unsolvated and solvated forms. The term 'solvate' is used herein to describe a molecular complex comprising the compound of the invention and a stoichiometric amount of one or more pharmaceutically acceptable solvent
30 molecules, for example, ethanol. The term 'hydrate' is employed when said solvent is water.

- Included within the scope of the invention are complexes such as clathrates, drug-host inclusion complexes wherein, in contrast to the aforementioned solvates, the drug and host are present in stoichiometric or non-stoichiometric amounts. Also included are complexes of the drug
35 containing two or more organic and/or inorganic components which may be in stoichiometric or non-stoichiometric amounts. The resulting complexes may be ionised, partially ionised, or non-ionised. For a review of such complexes, see J Pharm Sci, 64 (8), 1269-1288 by Halebian (August 1975).

Hereinafter all references to compounds of formula (1) include references to salts, solvates and complexes thereof and to solvates and complexes of salts thereof.

- 5 The compounds of the invention include compounds of formula (1) as hereinbefore defined, including all polymorphs and crystal habits thereof, prodrugs and isomers thereof (including optical, geometric and tautomeric isomers) as hereinafter defined and isotopically-labeled compounds of formula (1).
- 10 As indicated, so-called 'pro-drugs' of the compounds of formula (1) are also within the scope of the invention. Thus certain derivatives of compounds of formula (1) which may have little or no pharmacological activity themselves can, when administered into or onto the body, be converted into compounds of formula (1) having the desired activity, for example, by hydrolytic cleavage. Such derivatives are referred to as 'prodrugs'. Further information on the use of prodrugs may
- 15 be found in 'Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T. Higuchi and W. Stella) and 'Bioreversible Carriers in Drug Design', Pergamon Press, 1987 (ed. E. B. Roche, American Pharmaceutical Association).

- Prodrugs in accordance with the invention can, for example, be produced by replacing
- 20 appropriate functionalities present in the compounds of formula (1) with certain moieties known to those skilled in the art as 'pro-moieties' as described, for example, in "Design of Prodrugs" by H. Bundgaard (Elsevier, 1985).

Some examples of prodrugs in accordance with the invention include:

- 25 (i) where the compound of formula (1) contains a methyl group, an hydroxymethyl derivative thereof ($-\text{CH}_3 \rightarrow -\text{CH}_2\text{OH}$);
- (ii) where the compound of formula (1) contains an alkoxy group, an hydroxy derivative thereof ($-\text{OR} \rightarrow -\text{OH}$);
- (iii) where the compound of formula (1) contains a tertiary amino group, a secondary amino
- 30 derivative thereof ($-\text{NR}^1\text{R}^2 \rightarrow -\text{NHR}^1$ or $-\text{NHR}^2$);
- (iv) where the compound of formula (1) contains a secondary amino group, a primary derivative thereof ($-\text{NHR}^1 \rightarrow -\text{NH}_2$);
- (v) where the compound of formula (1) contains a phenyl moiety, a phenol derivative thereof ($-\text{Ph} \rightarrow -\text{PhOH}$); and
- 35 (vi) where the compound of formula (1) contains an amide group, a carboxylic acid derivative thereof ($-\text{CONH}_2 \rightarrow \text{COOH}$).

Further examples of replacement groups in accordance with the foregoing examples and examples of other prodrug types may be found in the aforementioned references.

Moreover, certain compounds of formula (1) may themselves act as prodrugs of other compounds of formula (1).

Also included within the scope of the invention are metabolites of compounds of formula (1), that is, compounds formed *in vivo* upon administration of the drug. Some examples of metabolites in accordance with the invention include

- (i) where the compound of formula (1) contains a secondary amino group, a primary derivative thereof ($-NHR^1 \rightarrow -NH_2$), and
- (ii) where the compound of formula (1) contains a phenyl moiety, a phenol derivative thereof ($-Ph \rightarrow -PhOH$).

Included within the scope of the present invention are all stereoisomers, geometric isomers and tautomeric forms of the compounds of formula (1), including compounds exhibiting more than one type of isomerism, and mixtures of one or more thereof. Also included are acid addition or base salts wherein the counterion is optically active, for example, *d*-lactate or *L*-lysine, or racemic, for example, *dl*-tartrate or *dl*-arginine.

Cis/trans isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallisation.

Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC).

Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound of formula (1) contains an acidic or basic moiety, an acid or base such as tartaric acid or 1-phenylethylamine. The resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person.

Chiral compounds of the invention (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% by volume of isopropanol, typically from 2% to 20%, and from 0 to 5% by volume of an alkylamine, typically 0.1% diethylamine. Concentration of the eluate affords the enriched mixture.

Stereoisomeric conglomerates may be separated by conventional techniques known to those skilled in the art - see, for example, "Stereochemistry of Organic Compounds" by E. L. Eliel (Wiley, New York, 1994).

- 5 The present invention includes all pharmaceutically acceptable isotopically-labelled compounds of formula (1) wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number which predominates in nature.
- 10 Examples of isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as ^2H and ^3H , carbon, such as ^{11}C , ^{13}C and ^{14}C , chlorine, such as ^{36}Cl , fluorine, such as ^{18}F , iodine, such as ^{123}I and ^{125}I , nitrogen, such as ^{13}N and ^{15}N , oxygen, such as ^{15}O , ^{17}O and ^{18}O , phosphorus, such as ^{32}P , and sulphur, such as ^{35}S .
- 15 Certain isotopically-labelled compounds of formula (1), for example those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, *i.e.* ^3H , and carbon-14, *i.e.* ^{14}C , are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
- 20 Substitution with heavier isotopes such as deuterium, *i.e.* ^2H , may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased *in vivo* half-life or reduced dosage requirements, and hence may be preferred in some circumstances.

Substitution with positron emitting isotopes, such as ^{11}C , ^{18}F , ^{15}O and ^{13}N , can be useful in

- 25 Positron Emission Topography (PET) studies for examining substrate receptor occupancy.

Isotopically-labeled compounds of formula (1) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagents in

- 30 place of the non-labeled reagent previously employed.

Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, *e.g.* D_2O , d_6 -acetone, d_8 -DMSO.

- 35 The compounds of formula (1), their pharmaceutically acceptable salts and/or derived forms, are valuable pharmaceutically active compounds, which are suitable for the therapy and prophylaxis of numerous disorders in which agonism of the β_2 receptor and antagonism of the muscarinic receptor may induce benefit, in particular the allergic and non-allergic airways diseases.

Compounds of the invention intended for pharmaceutical use may be administered as crystalline or amorphous products. They may be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, spray drying, or evaporative drying. Microwave or radio frequency drying may be used for this purpose.

5

They may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs (or as any combination thereof). Generally, they will be administered as a formulation in association with one or more pharmaceutically acceptable excipients. The term "excipient" is used herein to describe any ingredient other than the compound(s) of the invention. The choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.

10

Pharmaceutical compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in 'Remington's Pharmaceutical Sciences', 19th Edition (Mack Publishing Company, 1995).

15

The compounds of the invention may be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth.

20

Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews, multi- and nano-particulates, gels, solid solution, liposome, films, ovules, sprays and liquid formulations.

25

Liquid formulations include suspensions, solutions, syrups and elixirs. Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.

30

The compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 11 (6), 981-986, by Liang and Chen (2001).

35

For tablet dosage forms, depending on dose, the drug may make up from 1 weight % to 80 weight % of the dosage form, more typically from 5 weight % to 60 weight % of the dosage form.

In addition to the drug, tablets generally contain a disintegrant. Examples of disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinised starch and
5 sodium alginate. Generally, the disintegrant will comprise from 1 weight % to 25 weight %, preferably from 5 weight % to 20 weight % of the dosage form.

Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic
10 gums, polyvinylpyrrolidone, pregelatinised starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose. Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate.

15 Tablets may also optionally comprise surface active agents, such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc. When present, surface active agents may comprise from 0.2 weight % to 5 weight % of the tablet, and glidants may comprise from 0.2 weight % to 1 weight % of the tablet.

20 Tablets also generally contain lubricants such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulphate. Lubricants generally comprise from 0.25 weight % to 10 weight %, preferably from 0.5 weight % to 3 weight % of the tablet.

25 Other possible ingredients include anti-oxidants, colourants, flavouring agents, preservatives and taste-masking agents.

Exemplary tablets contain up to about 80% drug, from about 10 weight % to about 90 weight % binder, from about 0 weight % to about 85 weight % diluent, from about 2 weight % to about 10
30 weight % disintegrant, and from about 0.25 weight % to about 10 weight % lubricant.

Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt congealed, or extruded before
35 tableting. The final formulation may comprise one or more layers and may be coated or uncoated; it may even be encapsulated.

The formulation of tablets is discussed in *Pharmaceutical Dosage Forms: Tablets*, Vol. 1, by H. Lieberman and L. Lachman (Marcel Dekker, New York, 1980).

Consumable oral films for human or veterinary use are typically pliable water-soluble or water-swallowable thin film dosage forms which may be rapidly dissolving or mucoadhesive and typically comprise a compound of formula (1), a film-forming polymer, a binder, a solvent, a humectant, a plasticiser, a stabiliser or emulsifier, a viscosity-modifying agent and a solvent. Some components of the formulation may perform more than one function.

The compound of formula (1) may be water-soluble or insoluble. A water-soluble compound typically comprises from 1 weight % to 80 weight %, more typically from 20 weight % to 50 weight %, of the solutes. Less soluble compounds may comprise a greater proportion of the composition, typically up to 88 weight % of the solutes. Alternatively, the compound of formula (1) may be in the form of multiparticulate beads.

The film-forming polymer may be selected from natural polysaccharides, proteins, or synthetic hydrocolloids and is typically present in the range 0.01 to 99 weight %, more typically in the range 30 to 80 weight %.

Other possible ingredients include anti-oxidants, colorants, flavourings and flavour enhancers, preservatives, salivary stimulating agents, cooling agents, co-solvents (including oils), emollients, bulking agents, anti-foaming agents, surfactants and taste-masking agents.

Films in accordance with the invention are typically prepared by evaporative drying of thin aqueous films coated onto a peelable backing support or paper. This may be done in a drying oven or tunnel, typically a combined coater dryer, or by freeze-drying or vacuuming.

Solid formulations for oral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.

Suitable modified release formulations for the purposes of the invention are described in US Patent No. 6,106,864. Details of other suitable release technologies such as high energy dispersions and osmotic and coated particles are to be found in Pharmaceutical Technology Online, 25(2), 1-14, by Verma *et al* (2001). The use of chewing gum to achieve controlled release is described in WO 00/35298.

The compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internal organ. Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous. Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.

Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.

The preparation of parenteral formulations under sterile conditions, for example, by lyophilisation, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.

The solubility of compounds of formula (1) used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents.

Formulations for parenteral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release. Thus compounds of the invention may be formulated as a solid, semi-solid, or thixotropic liquid for administration as an implanted depot providing modified release of the active compound. Examples of such formulations include drug-coated stents and poly(*dl*-lactic-coglycolic)acid (PGLA) microspheres.

The compounds of the invention may also be administered topically to the skin or mucosa, that is, dermally or transdermally. Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibres, bandages and microemulsions. Liposomes may also be used. Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol. Penetration enhancers may be incorporated - see, for example, *J Pharm Sci*, 88 (10), 955-958 by Finnin and Morgan (October 1999).

Other means of topical administration include delivery by electroporation, iontophoresis, phonophoresis, sonophoresis and microneedle or needle-free (e.g. Powderject™, Bioject™, etc.) injection.

Formulations for topical administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.

The compounds of the invention can also be administered intranasally or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose,

or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aerosol spray from a pressurised container, pump, spray, atomiser (preferably an atomiser using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a suitable propellant, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane. For intranasal use, the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.

The pressurised container, pump, spray, atomizer, or nebuliser contains a solution or suspension of the compound(s) of the invention comprising, for example, ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.

Prior to use in a dry powder or suspension formulation, the drug product is micronised to a size suitable for delivery by inhalation (typically less than 5 microns). This may be achieved by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenisation, or spray drying.

Capsules (made, for example, from gelatin or hydroxypropylmethylcellulose), blisters and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound of the invention, a suitable powder base such as lactose or starch and a performance modifier such as *l*-leucine, mannitol, or magnesium stearate. The lactose may be anhydrous or in the form of the monohydrate, preferably the latter. Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.

A suitable solution formulation for use in an atomiser using electrohydrodynamics to produce a fine mist may contain from 1µg to 20mg of the compound of the invention per actuation and the actuation volume may vary from 1µl to 100µl. A typical formulation may comprise a compound of formula (1), propylene glycol, sterile water, ethanol and sodium chloride. Alternative solvents which may be used instead of propylene glycol include glycerol and polyethylene glycol.

Suitable flavours, such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium, may be added to those formulations of the invention intended for inhaled/intranasal administration.

Formulations for inhaled/intranasal administration may be formulated to be immediate and/or modified release using, for example, PGLA. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.

In the case of dry powder inhalers and aerosols, the dosage unit is determined by means of a valve which delivers a metered amount. Units in accordance with the invention are typically arranged to administer a metered dose or "puff" containing from 0.001mg to 10mg of the compound of formula (1). The overall daily dose will typically be in the range 0.001mg to 40mg
5 which may be administered in a single dose or, more usually, as divided doses throughout the day.

The compounds of formula (1) are particularly suitable for an administration by inhalation.

10 The compounds of the invention may be administered rectally or vaginally, for example, in the form of a suppository, pessary, or enema. Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate.

Formulations for rectal/vaginal administration may be formulated to be immediate and/or
15 modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.

The compounds of the invention may also be administered directly to the eye or ear, typically in the form of drops of a micronised suspension or solution in isotonic, pH-adjusted, sterile saline.
20 Other formulations suitable for ocular and aural administration include ointments, biodegradable (e.g. absorbable gel sponges, collagen) and non-biodegradable (e.g. silicone) implants, wafers, lenses and particulate or vesicular systems, such as niosomes or liposomes. A polymer such as crossed-linked polyacrylic acid, polyvinylalcohol, hyaluronic acid, a cellulosic polymer, for example, hydroxypropylmethylcellulose, hydroxyethylcellulose, or methyl cellulose, or a
25 heteropolysaccharide polymer, for example, gelatin gum, may be incorporated together with a preservative, such as benzalkonium chloride. Such formulations may also be delivered by iontophoresis.

Formulations for ocular/aural administration may be formulated to be immediate and/or modified
30 release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted, or programmed release.

The compounds of the invention may be combined with soluble macromolecular entities, such as cyclodextrin and suitable derivatives thereof or polyethylene glycol-containing polymers, in
35 order to improve their solubility, dissolution rate, taste-masking, bioavailability and/or stability for use in any of the aforementioned modes of administration.

Drug-cyclodextrin complexes, for example, are found to be generally useful for most dosage forms and administration routes. Both inclusion and non-inclusion complexes may be used. As

an alternative to direct complexation with the drug, the cyclodextrin may be used as an auxiliary additive, *i.e.* as a carrier, diluent, or solubiliser. Most commonly used for these purposes are alpha-, beta- and gamma-cyclodextrins, examples of which may be found in International Patent Applications Nos. WO 91/11172, WO 94/02518 and WO 98/55148.

5

Inasmuch as it may be desirable to administer a combination of active compounds, for example, for the purpose of treating a particular disease or condition, it is within the scope of the present invention that two or more pharmaceutical compositions, at least one of which contains a compound in accordance with the invention, may conveniently be combined in the form of a kit

10 suitable for coadministration of the compositions.

Thus the kit of the invention comprises two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (1) in accordance with the invention, and means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is the familiar blister pack used for the packaging of tablets, capsules and the like.

15

The kit of the invention is particularly suitable for administering different dosage forms, for example parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit typically comprises directions for administration and may be provided with a so-called memory aid.

20

For administration to human patients, the total daily dose of the compounds of the invention is typically in the range 0.001mg to 5000mg depending, of course, on the mode of administration. For example, an intravenous daily dose may only require from 0.001mg to 40mg. The total daily dose may be administered in single or divided doses and may, at the physician's discretion, fall outside of the typical range given herein.

25

These dosages are based on an average human subject having a weight of about 65kg to 70kg. The physician will readily be able to determine doses for subjects whose weight falls outside this range, such as infants and the elderly.

30

For the avoidance of doubt, references herein to "treatment" include references to curative, palliative and prophylactic treatment.

35

According to another embodiment of the present invention, the compounds of the formula (1), or pharmaceutically acceptable salts, derived forms or compositions thereof, can also be used as a combination with one or more additional therapeutic agents to be co-administered to a patient to

obtain some particularly desired therapeutic end result such as the treatment of pathophysiologically-relevant disease processes including, but not limited to (i) bronchoconstriction, (ii) inflammation, (iii) allergy, (iv) tissue destruction, (v) signs and symptoms such as breathlessness, cough. The second and more additional therapeutic agents may also
5 be a compound of the formula (1), or a pharmaceutically acceptable salt, derived forms or compositions thereof, or one or more β 2 agonists, muscarinic antagonists or compounds active as beta 2 agonist and as muscarinic antagonist known in the art. More typically, the second and more therapeutic agents will be selected from a different class of therapeutic agents.

10 As used herein, the terms "co-administration", "co-administered" and "in combination with", referring to the compounds of formula (1) and one or more other therapeutic agents, is intended to mean, and does refer to and include the following:

- 15 • simultaneous administration of such combination of compound(s) of formula (1) and therapeutic agent(s) to a patient in need of treatment, when such components are formulated together into a single dosage form which releases said components at substantially the same time to said patient,
- 20 • substantially simultaneous administration of such combination of compound(s) of formula (1) and therapeutic agent(s) to a patient in need of treatment, when such components are formulated apart from each other into separate dosage forms which are taken at substantially the same time by said patient, whereupon said components are released at substantially the same time to said patient,
- 25 • sequential administration of such combination compound(s) of formula (1) and therapeutic agent(s) to a patient in need of treatment, when such components are formulated apart from each other into separate dosage forms which are taken at consecutive times by said patient with a significant time interval between each administration, whereupon said components are released at substantially different times to said patient; and
- 30 • sequential administration of such combination of compound(s) of formula (1) and therapeutic agent(s) to a patient in need of treatment, when such components are formulated together into a single dosage form which releases said components in a controlled manner whereupon they are concurrently, consecutively, and/or overlappingly administered at the same and/or different times by said patient,

where each part may be administered by either the same or different route.

35 Suitable examples of other therapeutic agents which may be used in combination with the compound(s) of formula (1), or pharmaceutically acceptable salts, derived forms or compositions thereof, include, but are by no means limited to :

- (a) 5-Lipoxygenase (5-LO) inhibitors or 5-lipoxygenase activating protein (FLAP) antagonists,
- (b) Leukotriene antagonists (LTRAs) including antagonists of LTB_4 , LTC_4 , LTD_4 , and LTE_4 ,

- (c) Histamine receptor antagonists including H1 and H3 antagonists,
- (d) α_1 - and α_2 -adrenoceptor agonist vasoconstrictor sympathomimetic agents for decongestant use.
- (e) PDE inhibitors, e.g. PDE3, PDE4 and PDE5 inhibitors,
- 5 (f) Theophylline,
- (g) Sodium cromoglycate,
- (h) COX inhibitors both non-selective and selective COX-1 or COX-2 inhibitors (NSAIDs),
- (i) Prostaglandin receptor antagonists and inhibitors of prostaglandin synthase.
- (j) Oral and inhaled glucocorticosteroids,
- 10 (k) Dissociated agonists of the corticoid receptor (DAGR);
- (l) Monoclonal antibodies active against endogenous inflammatory entities,
- (m) Anti-tumor necrosis factor (anti-TNF- α) agents,
- (n) Adhesion molecule inhibitors including VLA-4 antagonists,
- (o) Kinin-B₁ - and B₂-receptor antagonists,
- 15 (p) Immunosuppressive agents, including inhibitors of the IgE pathway and cyclosporine,
- (q) Inhibitors of matrix metalloproteases (MMPs),
- (r) Tachykinin NK₁, NK₂ and NK₃ receptor antagonists,
- (s) Protease inhibitors such as elastase inhibitors,
- (t) Adenosine A2a receptor agonists and A2b antagonists,
- 20 (u) Inhibitors of urokinase,
- (v) Compounds that act on dopamine receptors, such as D2 agonists,
- (w) Modulators of the NF κ B pathway, such as IKK inhibitors,
- (x) modulators of cytokine signalling pathways such as p38 MAP kinase, PI3 kinase, JAK kinase, syk kinase, EGFR or MK-2,
- 25 (y) Agents that can be classed as mucolytics or anti-tussive,
- (z) Agents, which enhance responses to inhaled corticosteroids.
- (aa) Antibiotics and antiviral agents effective against micro-organisms which can colonise the respiratory tract,
- (bb) HDAC inhibitors,
- 30 (cc) CXCR2 antagonists,
- (dd) Integrin antagonists,
- (ee) Chemokines,
- (ff) Epithelial sodium channel (ENaC) blockers or Epithelial sodium channel (ENaC) inhibitors,
- (gg) P2Y2 Agonists and other Nucleotide receptor agonists,
- 35 (hh) Inhibitors of thromboxane,
- (ii) Niacin, and
- (jj) Adhesion factors including VLAM, ICAM, and ELAM.

According to the present invention, combination of the compounds of formula (1) with:

- H3 antagonists,
- PDE4 inhibitors,
- Oral and inhaled glucocorticosteroids,
- Dissociated agonists of the corticoid receptor (DAGR),
- 5 - Adenosine A2a receptor agonists,
- Modulators of cytokine signalling pathways such as p38, MAP kinase, PI3 kinase, JAK kinase, syk kinase, EGFR or MK-2, or
- Leukotriene antagonists (LTRAs) including antagonists of LTB₄, LTC₄, LTD₄, and LTE₄, are preferred.

10 According to the present invention, combination of the compounds of formula (1) with glucocorticosteroids, including prednisone, prednisolone, flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, ciclesonide, mometasone furoate and mometasone furoate monohydrate and in particular inhaled glucocorticosteroids with reduced systemic side effects, are further preferred.

15 It is to be appreciated that all references herein to treatment include curative, palliative and prophylactic treatment.

The compounds of formula (1) have the ability to interact with the β 2 receptor and cholinergic muscarinic receptors, and thereby have a wide range of therapeutic applications, as described
20 further below, because of the essential role which the β 2 receptor and muscarinic receptors play in the physiology of all mammals.

Therefore, a further aspect of the present invention relates to the compounds of formula (1), or pharmaceutically acceptable salts, derived forms or compositions thereof, for use in the
25 treatment of diseases, disorders, and conditions in which the β 2 receptor and /or muscarinic receptors are involved. More specifically, the present invention also concerns the compounds of formula (1), or pharmaceutically acceptable salts, derived forms or compositions thereof, for use in the treatment of diseases, disorders, and conditions selected from the group consisting of:


- asthma of whatever type, etiology, or pathogenesis, in particular asthma that is a
30 member selected from the group consisting of atopic asthma, non-atopic asthma, allergic asthma, atopic bronchial IgE-mediated asthma, bronchial asthma, essential asthma, true asthma, intrinsic asthma caused by pathophysiologic disturbances, extrinsic asthma caused by environmental factors, essential asthma of unknown or inapparent cause, non-atopic asthma, bronchitic asthma, emphysematous asthma,
35 exercise-induced asthma, allergen induced asthma, cold air induced asthma, occupational asthma, infective asthma caused by bacterial, fungal, protozoal, or viral infection, non-allergic asthma, incipient asthma, wheezy infant syndrome and bronchiolitis,

- chronic or acute bronchoconstriction, chronic bronchitis, small airways obstruction, and emphysema,
- obstructive or inflammatory airways diseases of whatever type, etiology, or pathogenesis, in particular an obstructive or inflammatory airways disease that is a member selected from the group consisting of chronic eosinophilic pneumonia, chronic obstructive pulmonary disease (COPD), COPD that includes chronic bronchitis, pulmonary emphysema or dyspnea associated or not associated with COPD, COPD that is characterized by irreversible, progressive airways obstruction, adult respiratory distress syndrome (ARDS), exacerbation of airways hyper-reactivity consequent to other drug therapy and airways disease that is associated with pulmonary hypertension,
- bronchitis of whatever type, etiology, or pathogenesis, in particular bronchitis that is a member selected from the group consisting of acute bronchitis, acute laryngotracheal bronchitis, arachidic bronchitis, catarrhal bronchitis, croupus bronchitis, dry bronchitis, infectious asthmatic bronchitis, productive bronchitis, staphylococcus or streptococcal bronchitis and vesicular bronchitis,
- acute lung injury,
- bronchiectasis of whatever type, etiology, or pathogenesis, in particular bronchiectasis that is a member selected from the group consisting of cylindric bronchiectasis, sacculated bronchiectasis, fusiform bronchiectasis, capillary bronchiectasis, cystic bronchiectasis, dry bronchiectasis and follicular bronchiectasis.


A still further aspect of the present invention also relates to the use of the compounds of formula (1), or pharmaceutically acceptable salts, derived forms or compositions thereof, for the manufacture of a drug having a $\beta 2$ agonist activity and an M3 antagonist activity. In particular, the present inventions concerns the use of the compounds of formula (1), or pharmaceutically acceptable salts, derived forms or compositions thereof, for the manufacture of a drug for the treatment of diseases and/or conditions involving the beta 2 and M3 receptors, in particular the diseases and/or conditions listed above.

As a consequence, the present invention provides a particularly interesting method to treat a mammal, including a human being, with an effective amount of a compound of formula (1), or a pharmaceutically acceptable salt, derived form or composition thereof. More precisely, the present invention provides a particularly interesting method for the treatment of a $\beta 2$ -mediated diseases and/or conditions involving the beta 2 and M3 receptors, in a mammal, including a human being, in particular the diseases and/or conditions listed above, comprising administering said mammal with an effective amount of a compound of formula (1), its pharmaceutically acceptable salts and/or derived forms.

The following examples illustrate the preparation of the compounds of the formula (1):

Preparation 1Di-tert-butyl (9-bromononyl)imidocarbonate

- 5 Sodium hydride (1.31g of a 60% dispersion in oil, 30.0mmol) was added in one portion to a stirred solution of di-tert-butyl iminodicarbamate (6.50g, 30.0mmol) in *N,N*-dimethylformamide (5ml) at 0°C under nitrogen. The reaction was stirred for 5 minutes at 0°C and then stirred at room temperature for 30 minutes. The reaction was cooled to 0°C and 1,9-dibromononane (8.60g, 30.0mmol) added dropwise, the reaction was allowed to warm to room temperature and
- 10 stirred for 3 days. Diethyl ether (50ml) and water (20ml) were cautiously added and the organics separated, the aqueous layer was washed with diethyl ether (50ml) and the combined organics dried (magnesium sulphate) and the solvent removed *in vacuo* to yield a clear oil. The oil was purified by column chromatography on silica gel eluting with diethyl ether:hexane (10/90 by volume) to furnish the title compound as a colourless oil, 5.80g.
- 15 ¹H NMR (400MHz, CD₃OD): δ = 1.30 (10H, m), 1.50 (20H, m), 1.83 (2H, m), 3.42 (2H, t), 3.58 (2H, t) ppm.


Preparation 2Di-tert-butyl [10-[4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl]dec-9-en-1-yl]imidodicarbonate

- Di-tert-butyl (9-bromononyl)imidocarbonate (Preparation 1, 1.80g, 4.26mmol) and triphenylphosphine (2.00g, 7.63mmol) were dissolved in acetonitrile (40ml) and heated under reflux for 48 hours. The reaction was cooled to room temperature and the solvent reduced *in vacuo* to 8ml. The reaction was heated under reflux for 12 hours and the reaction cooled to room temperature. The solvent was removed *in vacuo* to furnish the intermediate phosphonium salt as a gum. The gum (1.70g, 2.48mmol) was dissolved in tetrahydrofuran (15ml) and cooled to -78°C under a nitrogen atmosphere. *n*-Butyl lithium (0.90ml of a 2.5M solution in hexanes,
- 25

- 2.25mmol) was added dropwise to give an orange solution which was then warmed to 0°C and stirred for 45 minutes. The reaction was cooled to -78°C and a solution of 4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]benzaldehyde (Prepared according to WO 2005/012227, 320mg, 0.75mmol) in tetrahydrofuran (5ml) was added dropwise and the reaction stirred at -
- 5 78°C for 10 minutes. The reaction was warmed to room temperature and stirred for 12 hours and then poured onto ethyl acetate (30ml) and water (20ml). The organics were separated, dried (magnesium sulphate) and the solvent removed *in vacuo*, the residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (90/10/1.0 by volume) to furnish the title compound as a white gum, 140mg.
- 10 LRMS: m/z 755.7 $[M+H]^+$.

Preparation 3

10-{4-(Benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl}dec-9-en-1-amine




- 15 Hydrochloric acid (10.0ml of a 2M solution in diethyl ether) was added in one portion to a stirred solution of di-tert-butyl [10-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl}dec-9-en-1-yl]imidodicarbonate (Preparation 2, 450mg, 0.59mmol) at room temperature in dichloromethane (5ml) under a nitrogen atmosphere. The reaction was stirred for 2 hours and the solvent removed *in vacuo*, the residue was dissolved in ethyl acetate (30ml) and
- 20 saturated aqueous sodium hydrogen carbonate (20ml). The organics were separated, washed with water (10ml), dried (magnesium sulphate) and the solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (90/10/1.0 by volume) to furnish the title compound as a glass, 180mg.
- LRMS: m/z 556 $[M+H]^+$.

25

Preparation 4


N-[2-(benzyloxy)-5-[(1R)-2-{[10-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl}dec-9-en-1-yl]amino}-1-{tert-butyl(dimethyl)silyl}oxy}ethyl]phenyl]methanesulfonamide



- 10-[4-(Benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl]dec-9-en-1-amine (Preparation 3, 170mg, 0.33mmol) and N-{2-(benzyloxy)-5-[(1R)-2-bromo-1-[(tert-butyl(dimethyl)silyl]oxy]ethyl]phenyl}methanesulfonamide (Prepared according to WO2005/080324, 180mg, 0.33mmol) were heated at 90°C in dimethylsulfoxide (0.5ml) for 12 hours. Ethyl acetate (20ml) and water (10ml) were added and the organics separated, washed with water (10ml), dried (magnesium sulphate) and the solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (80/20/2.0 by volume) to furnish the title compound as a glass, 90mg.
- 10 LRMS: m/z 989 $[M+H]^+$.

Preparation 5

tert-Butyl [2-[4-(allyloxy)phenyl]ethyl]carbamate




- 15 Allyl bromide (2.10ml, 24.8mmol) was added in one portion to a suspension of potassium carbonate (4.40g, 31.8mmol) and tert-butyl [2-(4-hydroxyphenyl)ethyl]carbamate (Prepared according to Journal of Organic Chemistry 1999, 64, 1074, 5.00g, 21.1mmol) in acetonitrile (50ml) at room temperature. The reaction was stirred for 12 hours and the solvent removed *in vacuo*. Diethyl ether (50ml) and water (20ml) were added and the organics separated, washed with water (20ml), dried (magnesium sulphate) and the solvent removed *in vacuo* to yield a clear oil. The oil was purified by column chromatography on silica gel eluting with ethyl acetate:pentane (25/75 by volume) to furnish the title compound as a white solid, 3.80g.
- 20 ^1H NMR (400MHz, CDCl_3): δ = 1.42 (9H, s), 2.78 (2H, m), 3.37 (2H, m), 4.58 (3H, m), 5.28 (1H, dd), 5.40 (1H, dd), 6.10 (1H, m), 6.84 (2H, d), 7.10 (2H, d) ppm.

25

Preparation 6

tert-Butyl [2-(4-[(2E)-3-[4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl]prop-2-en-1-yl]oxy]phenyl)ethyl]carbamate




- (3R)-3-[2-(benzyloxy)-5-bromophenyl]-N,N-diisopropyl-3-phenylpropan-1-amine (Prepared according to WO1994/11337, 800mg, 1.66mmol), tert-Butyl {2-[4-(allyloxy)phenyl]ethyl}carbamate (Preparation 5, 924mg, 3.33mmol), palladium acetate (37mg, 0.16mmol), tri(o-tolyl)phosphine (101mg, 0.33mmol), and diisopropylethylamine (435ul, 2.50mmol) were heated at 90°C in acetonitrile (10ml) under a nitrogen atmosphere for 12 hours. The reaction was cooled to room temperature and poured onto ethyl acetate (30ml) and water (20ml). The organics were separated, washed with saturated aqueous sodium hydrogen carbonate (20ml), water (20ml), brine (20ml), dried (magnesium sulphate) and the solvent removed *in vacuo*, the residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (90/10/1.0 by volume) to furnish the title compound as a glass, 475mg.

LRMS: m/z 677 [M+H]⁺.

15 Preparation 7

tert-Butyl {2-[4-(3-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl}propoxy)phenyl]ethyl}carbamate




- tert-Butyl [2-(4-[[[(2E)-3-[4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl]prop-2-en-1-yl]oxy]phenyl)ethyl]carbamate (Preparation 6, 475mg, 0.70mmol) was dissolved in ethanol (20ml) and 10% palladium on carbon (50mg) added. The reaction was heated to 40°C under 50psi of hydrogen for 4 hours. The reaction was cooled to room temperature and filtered through Arbocel™, the filtrate was collected and the solvent removed *in vacuo* to furnish the title compound as a glass, 400mg.

LRMS: m/z 589 [M+H]⁺.

Preparation 8


4-[3-[4-(2-aminoethyl)phenoxy]propyl]-2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenol



- tert-Butyl(2-[4-(3-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}propoxy)phenyl]ethyl)carbamate (Preparation 7, 400mg, 0.68mmol) was dissolved in dichloromethane (15ml) and hydrochloric acid (10ml of a 2M solution in diethyl ether) was added to the stirred solution at 0°C. After 3 hours the solvent was removed *in vacuo*, and ethyl acetate (20ml) and saturated aqueous sodium hydrogen carbonate (10ml) were added and the organics separated. The aqueous was washed with dichloromethane:methanol (90:10, by volume, 2x20ml) and the organics combined, dried (magnesium sulphate) and the solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (80/20/2.0 by volume) to furnish the title compound as a glass, 135mg.
- LRMS: m/z 489 [M+H]⁺.

15 Preparation 9


N-{2-(benzyloxy)-5-[(1R)-1-[(tert-butyl(dimethyl)silyl]oxy]-2-{2-[4-(3-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}propoxy)phenyl]ethyl}amino)ethyl]phenyl}methanesulfonamide



- 4-{3-[4-(2-aminoethyl)phenoxy]propyl}-2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenol (Preparation 8, 134mg, 0.27mmol) and N-{2-(benzyloxy)-5-[(1R)-2-bromo-1-[(tert-butyl(dimethyl)silyl]oxy]ethyl]phenyl}methanesulfonamide (Prepared according to WO2005/080324, 145mg, 0.28mmol) were heated at 90°C in dimethylsulfoxide (0.5ml) for 24 hours. Ethyl acetate (20ml) and water (10ml) were added and the organics separated. The aqueous was washed with ethyl acetate (20ml) and the combined organics washed with brine (10ml), dried (magnesium sulphate) and the solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (80/20/2.0 by volume) to furnish the title compound as a glass, 101mg.
- LRMS: m/z 923 [M+H]⁺.

Preparation 10

N-{5-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]-2-({2-[4-(3-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}propoxy)phenyl]ethyl}amino)ethyl]-2-hydroxyphenyl}methanesulfonamide




- N-{2-(benzyloxy)-5-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]-2-({2-[4-(3-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}propoxy)phenyl]ethyl}amino)ethyl]phenyl}methanesulfonamide (Preparation 9, 100mg, 0.11mmol) was dissolved in ethanol (10ml) and ammonium formate (68mg, 1.07mmol) and 10% palladium hydroxide on carbon (20mg) added. The stirred reaction was heated at 90°C for 2 hours, cooled to room temperature and filtered through Arbocel™, the filtrate was collected and the solvent removed *in vacuo* to furnish the title compound as a yellow glass, 98mg. LRMS: m/z 833 [M+H]⁺.

15

Preparation 11

tert-Butyl [2-(4-[(3E)-4-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl}but-3-en-1-yl]oxy)phenyl]ethyl]carbamate




- 20 tert-butyl [2-(4-hydroxyphenyl)ethyl]carbamate (Prepared according to Journal of Organic Chemistry 1999, 64, 1074, 1g, 4.2mmol) was dissolved in dimethylformamide (8ml) and potassium carbonate (698mg, 5.1mmol) was added, followed by 4-bromobut-1-ene (0.51ml, 5.1mmol) and the mixture was heated to 60°C. After 5 hours cooled to room temperature, then a further portion of potassium carbonate (698mg, 5.1mmol) and 4-bromobut-1-ene (0.51ml, 5.1mmol) were added and the mixture reheated to 60°C. After 18 hours cooled to room temperature, then a further portion of potassium carbonate (698mg, 5.1mmol) and 4-bromobut-1-ene (0.51ml, 5.1mmol) were added and the mixture reheated to 60°C. After a further 5 hours

- cooled to room temperature, then a further portion of potassium carbonate (350mg, 2.5mmol) and 4-bromobut-1-ene (0.25ml, 2.5mmol) were added and the mixture reheated to 60°C. Left to stir over night then cooled to room temperature, water added and extracted with ethyl acetate, dried (magnesium sulphate) and the solvent removed *in vacuo*, the residue was purified by column chromatography on silica gel eluting with pentane/ethyl acetate (80/20 by volume). The above reaction was repeated to yield 1.1g of intermediate, which was dissolved in acetonitrile (10ml), (3R)-3-[2-(benzyloxy)-5-bromophenyl]-N,N-diisopropyl-3-phenylpropan-1-amine (Prepared according to WO9411337, 1.2g, 2.5mmol), tris(2-methylphenyl)phosphine (760mg, 2.5mmol) and diisopropyl ethylamine (0.87ml, 4.99mmol) were added and the mixture degassed with a stream of argon gas. Palladium diacetate (280mg, 1.25mmol) was added and the mixture was heated to 90°C. After 5 hours, cooled to room temperature and left to stir over night. The mixture was filtered through Arbocel™ and the solvent removed *in vacuo*. Water was added and extracted with ethyl acetate the organic layer separated and dried (magnesium sulphate) and the solvent removed *in vacuo*, the residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (98/2/0.2 to 96/4/0.4 by volume) to yield the title compound as a colourless gum, 1.45g.
- LRMS: m/z 691 [M+H]⁺.

Preparation 12


- tert-Butyl [2-[4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-1-phenylpropyl]-4-hydroxyphenyl}butoxy)phenyl]ethyl]carbamate



- tert-butyl [2-(4-[(3E)-4-[4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl]but-3-en-1-yl]oxy)phenyl]ethyl]carbamate (Preparation 11, 725mg, 1.05mmol) was dissolved in ethanol (10ml), palladium hydroxide (20% by weight on carbon, 181mg, 0.25mmol) then ammonium formate (529mg, 8.39mmol) was added and heated to 80°C for 5 minutes then stirred at 75°C for 1 hour. Reaction was cooled to room temperature and the mixture was filtered through Arbocel™ and the solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (97/3/0.3 to 94/6/0.6 by volume) to yield the title compound as a white foam, 460mg.
- LRMS: m/z 603 [M+H]⁺.

Preparation 13


- 4-[4-[4-(2-Aminoethyl)phenoxy]butyl]-2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenol bis hydrochloride salt



- tert-butyl {2-[4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)phenyl]ethyl}carbamate (Preparation 12, 450mg, 0.75mmol) was dissolved in dichloromethane (10ml), hydrogen chloride (2M in diethyl ether, 6ml, 12mmol) was added followed by ethanol (1ml). After 3 days, solvents removed in vacuo to furnish the title compound as a yellow foam, 420mg.
LRMS: m/z 503 [M(free base)+H]⁺.

Preparation 14


- N-{2-(Benzyloxy)-5-[(1R)-1-[(tert-butyl(dimethyl)silyl]oxy)-2-({2-[4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)phenyl]ethyl}amino)ethyl]phenyl}methanesulfonamide



- 4-{4-[4-(2-aminoethyl)phenoxy]butyl}-2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenol bis hydrochloride salt (Preparation 13, 420mg, 0.73mmol), N-{2-(benzyloxy)-5-[(1R)-2-bromo-1-[(tert-butyl(dimethyl)silyl]oxy)ethyl]phenyl}methanesulfonamide (Prepared according to WO2005/080324, 375mg, 0.73mmol), sodium hydrogen carbonate (245mg, 2.92mmol) and potassium iodide (121mg, 0.73mmol) were added to acetonitrile (15ml) and heated to 90°C for 30 minutes and left at room temperature for 48 hours, water was added and extracted with ethyl acetate, dried (magnesium sulphate) and the solvent removed *in vacuo*, the residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (97/3/0.3 to 92/8/0.8 by volume) to furnish the title compound as a white foam, 207mg.
LRMS: m/z 937 [M+H]⁺.

Preparation 15

- N-{5-[(1R)-1-[(tert-Butyl(dimethyl)silyl]oxy)-2-({2-[4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)phenyl]ethyl}amino)ethyl]-2-hydroxyphenyl}methanesulfonamide



N-{2-(benzyloxy)-5-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]-2-({2-[4-(4-{3-[(1R)-3-

(diisopropylamino)-1-phenylpropyl]-4-


hydroxyphenyl]butoxy)phenyl]ethyl]amino)ethyl]phenyl]methanesulfonamide (Preparation 14,

5 200mg, 0.2mmol), and palladium hydroxide (20% by weight on carbon, 50mg, 0.07mmol) were dissolved in ethanol (5ml), then ammonium formate (74mg, 1.2mmol) was added and heated to 80°C for 5 minutes then stirred at 75°C for 1 hour. Reaction was cooled to room temperature and the mixture was filtered through Arbocel™ and the solvent removed *in vacuo* to yield the title compound as a white foam, 190mg.

10 LRMS: m/z 847 [M+H]⁺.

Preparation 16

4-(Benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenol




15 4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]benzaldehyde (Prepared according to WO2005012227, 1g, 2.32mmol) was dissolved in methanol (40ml), sulphuric acid (2M, 6ml) then hydrogen peroxide (30% by weight in water, 2ml) was added, and the reaction mixture was allowed to stir over night. The mixture was partitioned between water and diethyl ether, the organic layer was separated, washed with saturated sodium sulfite solution, dried (magnesium sulphate), filtered and the solvent removed *in vacuo* and the residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (24/1/0.1 to 23/2/0.2 by volume) to furnish the title compound as a buff foam, 560mg.

20 LRMS: m/z 418 [M+H]⁺.

25 Preparation 17


Di-tert-butyl (7-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenoxy}heptyl)imidodicarbonate



- 4-(Benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenol (Preparation 16, 150mg, 0.36mmol) was dissolved in dimethylformamide (2ml), caesium carbonate (140mg, 0.43mmol) was added and stirred at room temperature for 30 minutes. tert-Butyl (7-bromoheptyl)carbamate (Prepared according to J. Med. Chem., 1994, 137, p2537-2551; 170mg, 0.43mmol), dissolved in dimethylformamide (1ml), was added and heated to 70°C. After 2.5 hours caesium carbonate (70mg, 0.22mmol) was added and after a further 10 minutes tert-butyl (7-bromoheptyl)carbamate (70mg, 0.18mmol) was added. After 1 hour caesium carbonate (20mg, 0.06mmol) and tert-butyl (7-bromoheptyl)carbamate (35mg, 0.09mmol) were added and after 1 hour at 70°C the mixture was cooled to room temperature and stirred for 3 days before the addition of water and brine were added, the mixture extracted with ethyl acetate, dried (magnesium sulphate), filtered and the solvents removed *in vacuo* and the residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (98/2/0.2 to 95/5/0.5 by volume) to furnish the title compound as a colourless gum, 220mg. LRMS: m/z 731 $[M+H]^+$.

Preparation 18

- 7-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenoxy}heptan-1-amine bis hydrochloride salt




- Di-tert-butyl (7-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenoxy}heptyl)imidodicarbonate (Preparation 17, 220mg, 0.30mmol) was dissolved in dichloromethane (6ml) then hydrogen chloride (2M solution in diethyl ether, 6ml, 12mmol) was added and after 30

minutes, ethanol (1ml) was added and left over night. The solvent was removed *in vacuo* to furnish the title compound as a pale brown foam, 190mg.

LRMS: m/z 531 [M(free base)+H]⁺.

5 Preparation 19

N-{2-(Benzyloxy)-5-[(1R)-2-[(7-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenoxy}heptyl)amino]-1-[[tert-butyl(dimethyl)silyloxy]ethyl]phenyl]methanesulfonamide




- 7-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenoxy}heptan-1-amine bis
 10 hydrochloride salt (Preparation 18, 190mg, 0.31mmol), N-{2-(benzyloxy)-5-[(1R)-2-bromo-1-
 {[[tert-butyl(dimethyl)silyloxy]ethyl]phenyl]methanesulfonamide (Prepared according to
 WO2005/080324, 161mg, 0.32mmol), sodium hydrogen carbonate (106mg, 1.26mmol) and
 potassium iodide (52mg, 0.32mmol) were added to acetonitrile (5ml) and heated to 90°C for 24
 hours, then left at room temperature over night, water and brine were added and extracted with
 15 ethyl acetate, dried (magnesium sulphate) and the solvent removed *in vacuo*, the residue was
 purified by column chromatography on silica gel eluting with dichloromethane:methanol:880
 ammonia (98/2/0.2 to 92/8/0.8 by volume) to furnish the title compound as a colourless gum,
 100mg.

LRMS: m/z 965 [M+H]⁺.

20

Preparation 20

N-{5-[(1R)-1-[[tert-butyl(dimethyl)silyloxy]-2-[(7-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenoxy}heptyl)amino]ethyl]-2-hydroxyphenyl]methanesulfonamide




- 25 N-{2-(Benzyloxy)-5-[(1R)-2-[(7-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenoxy}heptyl)amino]-1-[[tert-

- butyl(dimethyl)silyl]oxy]ethyl]phenyl]methanesulfonamide (Preparation 19, 96mg, 0.10mmol) and palladium hydroxide (20% by weight on carbon, 25mg, 0.04mmol) were dissolved in ethanol (3ml), then ammonium formate (69mg, 1.1mmol) was added and heated to 80°C for 1 hour. The reaction was cooled to room temperature and the mixture was filtered through Arbocel™ and the solvent removed *in vacuo*. The residue was dissolved in dichloromethane (containing a trace of methanol) and washed with water (brine was added to aid in the separation), the organic layer was dried (magnesium sulphate), filtered, and the solvents removed *in vacuo* to yield the title compound as a white foam, 68mg.
- LRMS: m/z 785 [M+H]⁺.

10

Preparation 21


(3R)-3-[5-[2-[4-(2-aminoethyl)phenoxy]ethyl]-2-(benzyloxy)phenyl]-N,N-diisopropyl-3-phenylpropan-1-amine



- 15 2-[4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl]ethanol (Prepared according to WO9843942, 390mg, 0.88mmol) was dissolved in tetrahydrofuran (6ml), triphenylphosphine (344mg, 1.31mmol) then di-tert-butyl (E)-diazene-1,2-dicarboxylate (265mg, 1.31mmol) was added and the mixture was stirred for 20 minutes. tert-butyl [2-(4-hydroxyphenyl)ethyl]carbamate (Prepared according to WO2004/020415, 311mg, 1.31mmol)
- 20 was then added and the reaction was stirred over night. Hydrogen chloride (4M in diethyl ether, 5ml) was added and left to stir for 3 days, then hydrochloric acid (2M, 5ml) was added and after 1 hour the mixture was washed with diethyl ether, basified with 2N sodium hydroxide, extracted with diethyl ether, dried (magnesium sulphate), filtered and the solvents removed *in vacuo* and the residue was purified by column chromatography on silica gel eluting with
- 25 dichloromethane:methanol:880 ammonia (242/8/0.8 to 95/5/0.5 by volume) to furnish the title compound as a colourless oil, 100mg.
- LRMS: m/z 566 [M+H]⁺.

Preparation 22


- 30 N-[2-(benzyloxy)-5-[(1R)-2-[(2-[4-(2-aminoethyl)phenoxy]ethyl]amino)-1-phenylpropyl]phenyl]ethoxy]phenyl]ethyl]amino)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]phenyl]methanesulfonamide



- (3R)-3-[5-{2-[4-(2-aminoethyl)phenoxy]ethyl}-2-(benzyloxy)phenyl]-N,N-diisopropyl-3-phenylpropan-1-amine (Preparation 21, 95mg, 0.17mmol), N-{2-(benzyloxy)-5-[(1R)-2-bromo-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]phenyl}methanesulfonamide (WO2005/080324, 86mg, 0.17mmol), sodium hydrogen carbonate (42mg, 0.51mmol) and potassium iodide (28mg, 0.17mmol) were added to acetonitrile (2.5ml) and heated to reflux for 24 hours, then cooled to room temperature and the solvents removed *in vacuo*, the residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (242/8/0.8 to 95/5/0.5 by volume) to furnish the title compound as a white foam, 78mg.
- 10 LRMS: m/z 999 [M+H]⁺.

Preparation 23

6-(But-3-en-1-yloxy)hexanenitrile




- 15 6-Bromocapronitrile (1.19ml, 9.00mmol) and 3-buten-1-ol (946ul, 11.0mmol) were added to a stirred solution of potassium hydroxide (6.16g, 110mmol) and tetra-butylammonium bromide (434mg, 1.35mmol) in water (6ml) and dichloromethane (2ml). The reaction was stirred at room temperature for 4 days and then washed with diethyl ether (2x50ml). The combined organics were washed with water (3x30ml), dried (magnesium sulphate) and the solvent removed *in vacuo* to furnish the title compound as a colourless oil, 1.48g.
- 20 LRMS: m/z 168 [M+H]⁺.

Preparation 24

6-[(3E)-4-{4-(Benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl}but-3-en-1-yloxy]hexanenitrile


- 25



- (3R)-3-[2-(Benzyloxy)-5-bromophenyl]-N,N-diisopropyl-3-phenylpropan-1-amine (WO9411337, 1.21g, 2.50mmol) was dissolved in acetonitrile (8ml) and 6-(but-3-en-1-yloxy)hexanenitrile (Preparation 23, 708mg, 4.20mmol), diisopropylethylamine (0.64ml, 3.75mmol), palladium acetate (54mg, 0.25mmol) and tri(o-tolyl)phosphine (145mg, 0.25mmol) were added. The stirred reaction was heated at 90°C, under a nitrogen atmosphere, for 12 hours, cooled to room temperature and the solvent removed *in vacuo*. The residue was dissolved in ethyl acetate (50ml) and washed with saturated aqueous sodium hydrogen carbonate (50ml), brine (50ml), dried (magnesium sulphate) and the solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (95/5/0.5 by volume) to furnish the title compound as an oil, 960mg.
- LRMS: m/z 567 [M+H]⁺.

Preparation 25


6-(4-{3-[(1R)-3-(Diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)hexanenitrile



- 6-[[[(3E)-4-{4-(Benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl}but-3-en-1-yl]oxy]hexanenitrile (Preparation 24, 935mg, 1.65mmol) was dissolved in ethanol (20ml) and ammonium formate (1.90g, 30.0mmol) and 10% palladium hydroxide on carbon (190mg) added. The reaction was heated under reflux for 1 hour, cooled to room temperature and the reaction filtered through Arbocel™, the filtrate solvent was removed *in vacuo* to furnish the title compound as a colourless oil, 783mg.
- LRMS: m/z 479 [M+H]⁺.

Preparation 26

4-{4-[6-(Aminohexyl)oxy]butyl}-2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenol




- 6-(4-{3-[(1R)-3-(Diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)hexanenitrile (Preparation 25, 783mg, 1.64mmol) was dissolved in ethanol (20ml) and Raney nickel (100mg) added. The reaction was hydrogenated under 60psi at 40°C for 18 hours, cooled to room temperature and the reaction filtered through Arbocel™ and the filtrate solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with

dichloromethane:methanol:880 ammonia (90/10/1.0 by volume) to furnish the title compound, 506mg.

LRMS: m/z 481 [M+H]⁺.

5 Preparation 27


N-{2-(Benzyloxy)-5-[(1R)-1-[(tert-butyl(dimethyl)silyl]oxy]-2-{[6-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]butoxy}hexyl]amino}ethyl]phenyl}methanesulfonamide



- 4-{4-[(6-Aminoethyl)oxy]butyl}-2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenol (Preparation 26, 153mg, 0.32mmol) and N-{2-(benzyloxy)-5-[(1R)-2-bromo-1-[(tert-butyl(dimethyl)silyl]oxy]ethyl]phenyl}methanesulfonamide (Prepared according to WO2005/080324, 155mg, 0.32mmol), potassium iodide (10mg) and sodium hydrogen carbonate (104mg, 1.23mmol) were heated in propionitrile (3ml) at 90°C for 24 hours. The reaction was cooled to room temperature and the solvent removed *in vacuo*. The residue was dissolved in ethyl acetate (30ml), washed with aqueous saturated sodium hydrogen carbonate (30ml), water (30ml), brine (30ml) and dried (magnesium sulphate). The solvent was removed *in vacuo* and the oil was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (85/15/1.5 by volume) to furnish the title compound as a yellow oil, 130mg.
- LRMS (ES) : m/z 917 [M+H]⁺.

Preparation 28

N-{5-[(1R)-1-[(tert-Butyl(dimethyl)silyl]oxy]-2-{[6-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]butoxy}hexyl]amino}ethyl]-2-hydroxyphenyl}methanesulfonamide



25


N-{2-(Benzyloxy)-5-[(1R)-1-[(tert-Butyl(dimethyl)silyl]oxy]-2-{[6-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]butoxy}hexyl]amino}ethyl]phenyl}methanesulfonamide (Preparation 27, 530mg, 0.55mmol) was dissolved in ethanol and ammonium formate (700mg,

- 10.9mmol) and 10% palladium hydroxide on carbon (100mg) was added. The reaction was heated under reflux for 12 hours, cooled to room temperature and further ammonium formate (600mg, 9.37mmol) and 10% palladium hydroxide on carbon (60mg) added. The reaction was heated under reflux for 3 hours, cooled to room temperature and further 10% palladium hydroxide on carbon (60mg) added. The reaction was heated under reflux for 3 hours, cooled to room temperature and filtered through Arbocel™. The filtrate solvent was removed *in vacuo* and the oil was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (80/20/2.0 by volume) to furnish the title compound as a yellow oil, 420mg.
- 10 LRMS (ES) : m/z 827 $[M+H]^+$.

Preparation 29

N-{2-(benzyloxy)-5-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]-2-({2-[4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)phenyl]ethyl}amino)ethyl]phenyl}formamide


- 15 phenyl}formamide



- N-{2-(benzyloxy)-5-[(1R)-2-bromo-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]phenyl}formamide (Prepared according to US2005/215590, 500mg, 1.1mmol), 4-{4-[4-(2-aminoethyl)phenoxy]butyl}-2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenol bis hydrochloride salt (Preparation 13, 745mg, 1.3mmol), sodium hydrogen carbonate (550mg, 6.5mmol) and potassium iodide (50mg, 0.30mmol) were added to propionitrile (8ml) and heated to 90°C and left to stir overnight. Further 4-{4-[4-(2-aminoethyl)phenoxy]butyl}-2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenol (Preparation 13, 50mg, 0.087mmol) was then added and mixture stirred at 90°C for further 24 hours. After cooling, ethyl acetate and saturated aqueous sodium hydrogen carbonate were added, organics separated and washed with more saturated aqueous sodium hydrogen carbonate, then brine and then dried (magnesium sulphate) and solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (96:4:0.4 to 92:8:0.8 by volume) to furnish the title compound as an oil, 400mg.
- 20
- 25
- 30 LRMS: m/z 887 $[M+H]^+$.

Preparation 30

N-{5-[(1R)-1-[(tert-butyl(dimethyl)silyl]oxy)-2-[(2-[4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]butoxy)phenyl]ethyl]amino)ethyl]-2-hydroxyphenyl]formamide




- 5 N-{2-(benzyloxy)-5-[(1R)-1-[(tert-butyl(dimethyl)silyl]oxy)-2-[(2-[4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]butoxy)phenyl]ethyl]amino)ethyl]phenyl} formamide (Preparation 29, 400mg, 0.45mmol), ammonium formate (570mg, 9.0mmol) and 20% palladium hydroxide on carbon (60mg) were mixed in methanol (8ml) and stirred at 70°C for 1 hour under nitrogen. Further ammonium formate (500mg, 7.9mmol) and 20% palladium hydroxide on carbon (50mg) were then added and heating continued at 70°C for further 1 hour.
- 10 Reaction mixture was then cooled and filtered, the filtrate was collected and the solvent removed *in vacuo*. The residue was dissolved in methanol (8ml) and ammonium formate (500mg, 7.9mmol) and 20% palladium hydroxide on carbon (50mg) were added and stirred at 70°C for 1 hour under nitrogen. Reaction mixture was then cooled and filtered, the filtrate was collected and the solvent removed *in vacuo*. The residue was dissolved in ethyl acetate (25ml) and saturated aqueous sodium hydrogen carbonate (25ml). Organics were separated and washed with brine (15ml), dried (magnesium sulphate) and solvent was removed *in vacuo* to furnish the title compound as a yellow solid, 280mg.

LRMS: m/z 797 [M+H]⁺.

20

Preparation 31

8-(benzyloxy)-5-[(1R)-1-[(tert-butyl(dimethyl)silyl]oxy)-2-[(2-[4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]butoxy)phenyl]ethyl]amino)ethyl]quinolin-2(1H)-one




8-(benzyloxy)-5-[(1R)-2-bromo-1-[(tert-butyl(dimethyl)silyl]oxy]ethyl]quinolin-2(1H)-one (Prepared according to WO2005/092861, 530mg, 1.1mmol), 4-[4-[4-(2-aminoethyl)phenoxy]butyl]-2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenol bis hydrochloride salt (Preparation 13, 650mg, 1.3mmol), sodium hydrogen carbonate (550mg, 6.5mmol) and potassium iodide (50mg, 0.30mmol) were added to propionitrile (8ml) and heated to 90°C and left to stir overnight. After cooling, ethyl acetate and saturated aqueous sodium hydrogen carbonate were added, organics separated and washed with more saturated aqueous sodium hydrogen carbonate, then brine and then dried (magnesium sulphate) and solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (100/0/0 to 94/6/0.6 by volume) to furnish the title compound as an oil, 406mg.

LRMS: m/z 911 [M+H]⁺.

Preparation 32

5-[(1R)-1-[(tert-butyl(dimethyl)silyl]oxy]-2-[(2-[4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]butoxy)phenyl]ethyl]amino)ethyl]-8-hydroxyquinolin-2(1H)-one




8-(benzyloxy)-5-[(1R)-1-[(tert-butyl(dimethyl)silyl]oxy]-2-[(2-[4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]butoxy)phenyl]ethyl]amino)ethyl]quinolin-2(1H)-one (Preparation 31, 406mg, 0.45mmol), ammonium formate (560mg, 9.0mmol) and 20% palladium hydroxide on carbon (60mg) were mixed in methanol (8ml) and stirred at 70°C for 1 hour under nitrogen. Further ammonium formate (300mg, 4.8mmol) and 20% palladium hydroxide on carbon (30mg) were then added and heating continued at 70°C for further 1 hour. Reaction mixture was then cooled and filtered, the filtrate was collected and the solvent removed *in vacuo*. The residue was dissolved in methanol (8ml) and ammonium formate (560mg, 8.9mmol) and 20% palladium hydroxide on carbon (60mg) were added and stirred at 70°C for 1 hour under nitrogen. Reaction mixture was then cooled and filtered, the filtrate was collected and the solvent removed *in vacuo*. Residue was dissolved in ethyl acetate (25ml) and saturated aqueous sodium hydrogen carbonate (25ml). Organics were separated and washed with brine (15ml), dried (magnesium sulphate) and solvent was removed *in vacuo* to furnish the title compound as a yellow solid, 305mg.

LRMS: m/z 821 [M+H]⁺.

Preparation 33

4-{4-[4-(2-[[[(2R)-2-[3,5-bis(benzyloxy)phenyl]-2-[[tert-butyl(dimethyl)silyl]oxy]ethyl]amino]ethyl)phenoxy]butyl]-2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenol



5

{(1R)-1-[3,5-bis(benzyloxy)phenyl]-2-bromoethoxy}(tert-butyl)dimethylsilane (Prepared according to US2005/222128, 570mg, 1.1mmol), 4-{4-[4-(2-aminoethyl)phenoxy]butyl}-2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenol bis hydrochloride salt (Preparation 13, 746mg, 1.3mmol), sodium hydrogen carbonate (544mg, 6.48mmol) and potassium iodide (50mg, 0.30mmol) were added to propionitrile (8ml) and heated to 90°C and left to stir overnight. After cooling, ethyl acetate and saturated aqueous sodium hydrogen carbonate were added, organics separated and washed with more saturated aqueous sodium hydrogen carbonate, then brine and then dried (magnesium sulphate) and solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (100:0:0 to 94:6:0.6 by volume) to furnish the title compound as a yellow oil, 720mg.


15

LRMS: m/z 950 [M+H]⁺.

Preparation 34

5-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]-2-[(2-[4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]butoxy)phenyl]ethyl]amino)ethyl]benzene-1,3-diol

20




4-{4-[4-(2-[[[(2R)-2-[3,5-bis(benzyloxy)phenyl]-2-[[tert-butyl(dimethyl)silyl]oxy]ethyl]amino]ethyl)phenoxy]butyl]-2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenol (Preparation 33, 720mg, 0.76mmol), ammonium formate (960mg,

15.0mmol) and 20% palladium hydroxide on carbon (110mg) were mixed in methanol (8ml) and stirred at 70°C for 1 hour under nitrogen. Further ammonium formate (300mg, 4.75mmol) and 20% palladium hydroxide on carbon (30mg) were then added and heating continued at 70°C for further 1 hour. Reaction mixture was then cooled and filtered, the filtrate was collected and the solvent removed *in vacuo*. The residue was dissolved in methanol (8ml) and ammonium formate (900mg, 14mmol) and 20% palladium hydroxide on carbon (100mg) were added and stirred at 70°C for 1 hour under nitrogen. Reaction mixture was then cooled and filtered, the filtrate was collected and the solvent removed *in vacuo*. The residue was dissolved in ethyl acetate (25ml) and saturated aqueous sodium hydrogen carbonate (25ml). Organics were separated and washed with brine (15ml), dried (magnesium sulphate) and solvent was removed *in vacuo* to furnish the title compound as an off-white foam, 555mg.

LRMS: m/z 770 [M+H]⁺.

Preparation 35

15 tert-butyl [2-(3-hydroxyphenyl)ethyl]carbamate




3-(2-aminoethyl)phenol hydrochloride (3g, 17.3mmol) and triethylamine (6.02ml, 43.2mmol) dissolved in water (15ml) and 1,4-dioxan (45ml) and di-tert-butyl dicarbonate (4.52g, 1.20mmol) added. Mixture stirred at room temperature for 2 days. Diethyl ether (100ml) and hydrogen chloride (2M in water, 100ml) were then added and organics separated and washed with saturated aqueous sodium hydrogen carbonate (100ml), then brine (100ml) then dried (magnesium sulphate) and the solvent was removed *in vacuo* to furnish the title compound as a clear gum, 4.42g.

LRMS: m/z 260 [M+Na]⁺.

25

Preparation 36

2-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl}ethyl methanesulfonate




2-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl}ethanol (Prepared according to WO1998/43942, 1.0g, 2.25mmol) was dissolved in dichloromethane (20ml) and

30

N,N-diisopropyl ethylamine (1.8ml, 10mmol) added. The solution was then cooled to 0°C and methanesulphonyl chloride (0.42ml, 5.4mmol) was added. After stirring for 2 hours at 0°C the mixture was diluted with dichloromethane (20ml) and washed with water (50ml), brine (50ml) and then dried (magnesium sulphate) and the solvent removed *in vacuo* to yield the title compound as a yellow oil, 1.56g.
LRMS: m/z 524 [M+H]⁺.

Preparation 37


tert-butyl [2-[3-(2-[4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl]ethoxy)phenyl]ethyl]carbamate



tert-butyl [2-(3-hydroxyphenyl)ethyl]carbamate (Preparation 35, 1.7g, 5.96mmol), potassium carbonate (1.65g, 11.9mmol), potassium iodide (5.0g, 0.03mmol) and 2-[4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl]ethyl methanesulfonate (Preparation 36, 1.56g, 2.98mmol) were stirred in dimethylformamide (20ml) and stirred at 60°C overnight. After cooling, water (250ml) and diethyl ether (250ml) were added, organics separated and washed with water (100ml x 3), brine (150ml) then dried (magnesium sulphate) and the solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (100/0/0 to 90/10/1.0 by volume) to furnish the title compound as an oil, 1.3g.
LRMS: m/z 666 [M+H]⁺.

Preparation 38


(3R)-3-[5-[2-[3-(2-aminoethyl)phenoxy]ethyl]-2-(benzyloxy)phenyl]-N,N-diisopropyl-3-phenylpropan-1-amine



- tert-butyl {2-[3-(2-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl}ethoxy)phenyl]ethyl}carbamate (Preparation 37, 1.3g, 2.0mmol) dissolved in dichloromethane (5ml) and hydrochloric acid (4M in dioxin) added. Mixture stirred at room temperature for 3 hours under nitrogen. Solvent was removed *in vacuo*, and residue dissolved in dichloromethane (100ml) and
- 5 aqueous sodium hydroxide (1M, 100ml), aqueous separated and extracted with dichloromethane (100ml). Combined organics were dried (magnesium sulphate) and the solvent was removed *in vacuo* to furnish the title compound as an oil, 880mg.
- LRMS: m/z 565 [M+H]⁺.

10 Preparation 39

N-{2-(benzyloxy)-5-[(1R)-2-({2-[3-(2-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl}ethoxy)phenyl]ethyl}amino)-1-[(tert-butyl(dimethyl)silyl]oxy)ethyl]phenyl}methanesulfonamide




- 15 (3R)-3-[5-{2-[3-(2-aminoethyl)phenoxy]ethyl}-2-(benzyloxy)phenyl]-N,N-diisopropyl-3-phenylpropan-1-amine (Preparation 38, 340mg, 0.52mmol), potassium iodide (86mg, 0.52mmol), sodium hydrogen carbonate (175mg, 2.08mmol) and N-{2-(benzyloxy)-5-[(1R)-2-bromo-1-[(tert-butyl(dimethyl)silyl]oxy)ethyl]phenyl}methanesulfonamide (Prepared according to WO2005/080324, 270mg, 0.52mmol) were added to propionitrile (5ml) and stirred at 100°C
- 20 under nitrogen overnight. Mixture was cooled and water (100ml) and ethyl acetate (100ml) were added. Organics were separated and washed with brine (100ml), dried (magnesium sulphate) and the solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (100/0/0 to 85/15/1.5 by volume) to furnish the title compound as a glass, 257mg.
- 25 LRMS: m/z 999 [M+H]⁺.

Preparation 40

{2-(benzyloxy)-5-[(1R)-2-({2-[3-(2-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl}ethoxy)phenyl]ethyl}amino)-1-[(tert-butyl(dimethyl)silyl]oxy)ethyl]phenyl}methanol


- 30



- (3R)-3-[5-{2-[3-(2-aminoethyl)phenoxy]ethyl}-2-(benzyloxy)phenyl]-N,N-diisopropyl-3-phenylpropan-1-amine (Preparation 38, 470mg, 0.72mmol), potassium iodide (120mg, 0.72mmol), sodium hydrogen carbonate (240mg, 2.9mmol) and {2-(benzyloxy)-5-[(1R)-2-bromo-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]phenyl}methanol (Prepared according to WO2004/032921, 325mg, 0.72mmol) were stirred in propionitrile at 100°C for 24 hours under nitrogen. After cooling to room temperature, water (100ml) and ethyl acetate (100ml) were added, organics separated and washed with brine (100ml), dried (magnesium sulphate) and solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (100/0/0 to 85/15/1.5 by volume) to furnish the title compound as a brown glass, 450mg.
- LRMS: m/z 935 [M+H]⁺.

Preparation 41

- tert-butyl {2-[4-(2-[4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl]ethoxy)phenyl]ethyl}carbamate




- tert-butyl [2-(4-hydroxyphenyl)ethyl]carbamate (Prepared according to WO1998/43942, 3.8g, 7.3mmol), potassium carbonate (2.6g, 8.0mmol), potassium iodide (1.1g, 7.3mmol) and 2-[4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl]ethyl methanesulfonate (preparation 36, 1.56g, 2.98mmol) were stirred in toluene (20ml) and stirred at 120°C overnight. After cooling, water (80ml) and ethyl acetate (80ml) were added, organics separated and washed with saturated aqueous sodium hydrogen carbonate (40ml), brine (40ml) then dried (magnesium sulphate) and the solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (99/1/0.1 to 90/10/1.0 by volume) to furnish the title compound as an oil, 3.4g.

LRMS: m/z 666 $[M+H]^+$.

Preparation 42


- 5 (3R)-3-[5-{2-[4-(2-aminoethyl)phenoxy]ethyl}-2-(benzyloxy)phenyl]-N,N-diisopropyl-3-phenylpropan-1-amine bis hydrochloride salt



- tert-butyl {2-[4-(2-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl]ethoxy)phenyl]ethyl}carbamate (Preparation 41, 3.4g, 5.1mmol) was dissolved in dioxan (20ml) and treated with hydrochloric acid (4M in dioxan, 26ml). After stirring for 4 hours at room temperature
 10 the solvent was removed *in vacuo*. The residue was azeotroped twice from dichloromethane to yield the title compound as a brown solid, 3.
 LRMS: m/z 565 $[M+H]^+$.

Preparation 43

- 15 (3R)-3-[2-(benzyloxy)-5-{2-[4-(2-[(2R)-2-[3,5-bis(benzyloxy)phenyl]-2-{tert-butyl(dimethyl)silyloxy}ethyl]amino}ethyl)phenoxy]ethyl]phenyl]-N,N-diisopropyl-3-phenylpropan-1-amine



- (3R)-3-[5-{2-[4-(2-aminoethyl)phenoxy]ethyl}-2-(benzyloxy)phenyl]-N,N-diisopropyl-3-phenylpropan-1-amine bis hydrochloride salt (Preparation 42, 600mg, 0.94mmol), {(1R)-1-[3,5-bis(benzyloxy)phenyl]-2-bromoethoxy}(tert-butyl)dimethylsilane (Prepared according to US2005/222128, 500mg, 0.94mmol), potassium iodide (160mg, 0.94mmol), sodium hydrogen carbonate (480mg, 5.65mmol) were added to propionitrile (10ml) and stirred at 100°C under nitrogen overnight. The mixture was cooled and water (75ml) and ethyl acetate (75ml) were
 20 added. Organics were separated and washed with brine (25ml), dried (magnesium sulphate)
 25


and the solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (99/1/0.1 to 90/10/1 by volume) to furnish the title compound as a gum, 346mg.

LRMS: m/z 1012 $[M+H]^+$.

5

Preparation 44

5-[(1R)-1-[(tert-butyl(dimethyl)silyl]oxy)-2-[(2-{4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}ethoxy)phenyl]ethyl}amino)ethyl]benzene-1,3-diol




- 10 (3R)-3-[2-(benzyloxy)-5-[2-[4-(2-[(2R)-2-[3,5-bis(benzyloxy)phenyl]-2-[(tert-butyl(dimethyl)silyl]oxy)ethyl]amino)ethyl]phenoxy]ethyl]phenyl]-N,N-diisopropyl-3-phenylpropan-1-amine (Preparation 43, 346mg, 0.30mmol) was dissolved in methanol (30ml) and ammonium formate (380mg, 6.1mmol) and 20% palladium hydroxide on carbon (43mg) added. The stirred reaction was then heated at 90°C for 2 hours. After cooling to room temperature, mixture was
- 15 filtered and solvent removed *in vacuo*. The residue was then taken up in ethyl acetate (50ml) and saturated aqueous sodium hydrogen carbonate (50ml). The organics were separated, washed with brine then dried (magnesium sulphate) and the solvent removed *in vacuo* to yield the title compound as a yellow glass, 174mg.

LRMS: m/z 742 $[M+H]^+$.

20

Preparation 45

N-[2-(benzyloxy)-5-[(1R)-2-[(2-{4-(2-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl]ethoxy)phenyl]ethyl}amino)-1-[(tert-butyl(dimethyl)silyl]oxy)ethyl]phenyl]formamide




25

N-{2-(benzyloxy)-5-[(1R)-2-bromo-1-[(tert-butyl(dimethyl)silyl]oxy]ethyl]phenyl}formamide
(Prepared according to US2005/215590, 440mg, 0.95mmol) (3R)-3-[5-{2-[4-(2-
aminoethyl)phenoxy]ethyl}-2-(benzyloxy)phenyl]-N,N-diisopropyl-3-phenylpropan-1-amine bis
hydrochloride salt (Preparation 42, 600mg, 0.95mmol) potassium iodide (160mg, 0.94mmol),
5 sodium hydrogen carbonate (480mg, 5.65mmol) were added to propionitrile (10ml) and stirred at
100°C under nitrogen for 24 hours. The mixture was cooled and water (75ml) and ethyl acetate
(75ml) were added. Organics were separated and washed with brine, dried (magnesium
sulphate) and the solvent removed *in vacuo*. The residue was purified by column
chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (99/1/0.1 to
10 90/10/1 by volume) to furnish the title compound as a gum, 174mg.
LRMS: m/z 949 [M+H]⁺.

Preparation 46


N-{5-[(1R)-1-[(tert-butyl(dimethyl)silyl]oxy]-2-[(2-[4-(2-{3-[(1R)-3-(diisopropylamino)-1-
15 phenylpropyl]-4-hydroxyphenyl]ethoxy)phenyl]ethyl]amino)ethyl]-2-hydroxyphenyl}formamide



N-{2-(benzyloxy)-5-[(1R)-2-[(2-[4-(2-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-
phenylpropyl]phenyl]ethoxy)phenyl]ethyl]amino)-1-[(tert-
butyl(dimethyl)silyl]oxy]ethyl]phenyl}formamide (Preparation 45, 174mg, 0.18mmol) was
20 dissolved in methanol (20ml) and ammonium formate (230mg, 3.7mmol) and 20% palladium
hydroxide on carbon (26mg) added. The stirred reaction was then heated at 90°C for 2 hours.
After cooling to room temperature, the mixture was filtered and solvent removed *in vacuo*. The
residue was then taken up in ethyl acetate (50ml) and saturated aqueous sodium hydrogen
carbonate (50ml). The organics were separated, washed with brine then dried (magnesium
25 sulphate) and the solvent removed *in vacuo* to yield the title compound as a yellow glass,
180mg.
LRMS: m/z 769 [M+H]⁺.

Preparation 47


8-(benzyloxy)-5-[(1R)-2-[(2-[4-(2-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-
30 phenylpropyl]phenyl]ethoxy)phenyl]ethyl]amino)-1-[(tert-butyl(dimethyl)silyl]oxy]ethyl]quinolin-
2(1H)-one



- (3R)-3-[5-{2-[4-(2-aminoethyl)phenoxy]ethyl}-2-(benzyloxy)phenyl]-N,N-diisopropyl-3-phenylpropan-1-amine bis hydrochloride salt (Preparation 42, 800mg, 1.25mmol), 8-(benzyloxy)-5-[(1R)-2-bromo-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]quinolin-2(1H)-one (Prepared according to WO2005/092861, 615mg, 1.25mmol), potassium iodide (210mg, 1.25mmol), sodium hydrogen carbonate (630mg, 7.5mmol) were added to propionitrile (15ml) and stirred at 100°C under nitrogen overnight. The mixture was cooled and water (100ml) and ethyl acetate (100ml) added. Organics were separated and washed with water (100ml) then brine (50ml), dried (magnesium sulphate) and the solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (100/0/0 to 90/10/1 by volume) to furnish the title compound as a gum, 297mg.
- LRMS: m/z 973 $[M+H]^+$.

Preparation 48

- 15 {2-(benzyloxy)-5-[(1R)-2-[(2-[4-(2-(4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl]ethoxy)phenyl]ethyl]amino)-1-[(tert-butyl(dimethyl)silyl]oxy]ethyl]phenyl]methanol}




- 20 tert-butyl {2-[4-(2-[4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl]ethoxy)phenyl]ethyl]carbamate (Preparation 41, 830mg, 1.25mmol) was treated with hydrochloric acid (8ml of a 4M solution in 1,4-dioxane) and stirred at room temperature overnight, and the solvent was removed *in vacuo*. The residue was dissolved in acetonitrile (8ml) and {2-(benzyloxy)-5-

- 5 [(1R)-2-bromo-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]phenyl]methanol (Sali patent, 560mg, 1.24mmol) and sodium hydrogen carbonate (368mg, 4.34mmol) added. Mixture heated to 85°C and stirred overnight. Reaction was cooled to room temperature and ethyl acetate and water added, the aqueous layer was separated and washed with ethyl acetate and the combined organics dried (magnesium sulphate) and the solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (92.5/7.5/1 by volume) to furnish the title compound as a gum, 280mg.
- LRMS: m/z 936 [M+H]⁺.

10 Preparation 49


4-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]-2-[(2-[4-(2-[3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]ethoxy)phenyl]ethyl]amino)ethyl]-2-(hydroxymethyl)phenol



- 15 {2-(benzyloxy)-5-[(1R)-2-[(2-[4-(2-[4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl]ethoxy)phenyl]ethyl]amino)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]phenyl} methanol (Preparation 48, 280mg, 0.30mmol) was dissolved in ethanol (6ml) and palladium hydroxide (20% by weight on carbon, 14mg, 0.02mmol) was added. The reaction was the hydrogenated under 40psi at room temperature for 18hours, cooled to room temperature and
- 20 the reaction filtered through Celite™ and the filtrate solvent removed *in vacuo* to furnish the title compound as a gum, 235mg.
- LRMS: m/z 756 [M+H]⁺.

Preparation 50

- 25 di-tert-butyl oct-7-en-1-ylimidodicarbonate




To a stirred suspension of sodium hydride (840mg of a 60% dispersion in oil, 21.0mmol) in *N,N*-dimethylformamide (40ml) was added in one portion di-*tert*-butyl iminodicarbamate (4.56g,

- 21.0mmol). After stirring for 40mins, 8-bromooct-1-ene (3.50ml, 21mmol) was added and mixture was stirred at room temperature overnight. The solvent was removed *in vacuo* and the residue dissolved in water and ethyl acetate. The organic layer was separated and washed with water then brine, dried (magnesium sulphate) and the solvent removed *in vacuo*. The residue
- 5 was purified by column chromatography on silica gel eluting with diethyl ether:pentane (1/99 to 6/94 by volume) to furnish the title compound as a clear oil, 5.51g.

Preparation 51

- 10 di-tert-butyl [(7E)-8-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl}oct-7-en-1-yl]imidodicarbonate




- di-tert-butyl oct-7-en-1-ylimidodicarbonate (Preparation 48, 649mg, 1.98mmol), (3R)-3-[2-(benzyloxy)-5-bromophenyl]-N,N-diisopropyl-3-phenylpropan-1-amine (Prepared according to WO1994/11337, 560mg, 1.16mmol), palladium diacetate (27mg, 0.12mmol), tris(2-methylphenyl)phosphine (73mg, 0.24mmol) and N,N-diisopropylethylamine (0.304ml, 1.75mmol)
- 15 were added to acetonitrile (6ml) and the mixture was heated to 90°C and left to stir overnight under nitrogen. Mixture was cooled and saturated aqueous sodium hydrogen carbonate and ethyl acetate were added. Organics separated and washed with saturated aqueous sodium hydrogen carbonate, brine, dried (magnesium sulphate) and the solvent removed *in vacuo*. The
- 20 residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (100/0/0 to 96/4/0.4 by volume) to furnish the title compound as a oil, 530mg.

LRMS: m/z 727 $[M+H]^+$.

25 Preparation 52


di-tert-butyl (8-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}octyl)imidodicarbonate



- di-tert-butyl [(7E)-8-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl}oct-7-en-1-yl]imidodicarbonate (Preparation 51, 530mg, 0.73mmol), palladium hydroxide (20% by weight on carbon, 100mg, 0.14mmol) and ammonium formate (1.1g, 17mmol) were dissolved in ethanol (20ml) and heated to 70°C for 3 hours. Reaction mixture was cooled and filtered and the solvent removed *in vacuo* to yield the title compound as a clear oil, 340mg.
- LRMS: m/z 640 [M+H]⁺.

Preparation 53


4-(8-aminooctyl)-2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenol



- Di-tert-butyl (8-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}octyl)imidodicarbonate (Preparation 52, 340mg, 0.53mmol) was dissolved in dichloromethane (5ml) and hydrochloric acid (5.0ml of a 2M solution in diethyl ether) was added, and the mixture stirred overnight at room temperature. Solvent was removed *in vacuo* and the residue dissolved in a mixture of ethyl acetate and saturated aqueous sodium hydrogen carbonate. Organic layer was separated, dried (magnesium sulphate) and solvent removed *in vacuo* to yield the title compound as a yellow oil, 170mg.
- LRMS: m/z 439 [M+H]⁺.

Preparation 54

N-[2-(benzyloxy)-5-[(1R)-1-[(tert-butyl(dimethyl)silyl]oxy)-2-[(8-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}octyl)amino]ethyl]phenyl]methanesulfonamide



- 4-(8-aminooctyl)-2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenol (Preparation 53, 170mg, 0.39mmol) and N-[2-(benzyloxy)-5-[(1R)-2-bromo-1-[(tert-butyl(dimethyl)silyl]oxy)ethyl]phenyl]methanesulfonamide (Prepared according to WO2005/080324, 191mg, 0.37mmol) were heated at 90°C in dimethylsulfoxide (0.5ml) overnight. Ethyl acetate and saturated aqueous sodium hydrogen carbonate were added and the organics separated, washed with saturated aqueous sodium hydrogen carbonate, brine, dried


(magnesium sulphate) and the solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (99/1/0.1 to 95/5/0.5 by volume) to furnish the title compound as a yellow oil, 90mg.

LRMS: m/z 872 $[M+H]^+$.

5

Preparation 55

N-(5-((1R)-1-((tert-butyl(dimethyl)silyl)oxy)-2-((8-{3-((1R)-3-(diisopropylamino)-1-phenylpropyl)-4-hydroxyphenyl}octyl)amino)ethyl)-2-hydroxyphenyl)methanesulfonamide




- 10 N-[2-(benzyloxy)-5-((1R)-1-((tert-butyl(dimethyl)silyl)oxy)-2-((8-{3-((1R)-3-(diisopropylamino)-1-phenylpropyl)-4-hydroxyphenyl}octyl)amino)ethyl)phenyl]methanesulfonamide (Preparation 54, 90mg, 0.10mmol), ammonium formate (130mg, 2.0mmol) and 20% palladium hydroxide on carbon (20mg) were mixed in ethanol (3ml) and heated to 70°C overnight. Reaction mixture was then cooled and filtered. The filtrate was collected and the solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (98/2/0.2 to 91/9/0.9 by volume) to furnish the title compound as a gum to furnish the title compound as a glass, 82mg.

LRMS: m/z 783 $[M+H]^+$.

20 Preparation 56

tert-butyl [2-[4-(pent-4-en-1-yloxy)phenyl]ethyl]carbamate




- 25 tert-butyl [2-(4-hydroxyphenyl)ethyl]carbamate (Prepared according to Journal of Organic Chemistry 1999, 64, 1074, 1.0g, 4.21 mmol) was dissolved in dimethylformamide (8ml) and potassium carbonate (1.2g, 8.4mmol) was added, followed 15 minutes later by 5-bromopent-1-ene (0.99ml, 8.4mmol), and the mixture stirred at 60°C overnight.

After cooling to room temperature, water was added and extracted with diethyl ether, dried (magnesium sulphate) and the solvent removed *in vacuo*, to yield the title compound as a white solid, 1.2g.

LRMS: m/z 328 $[M+Na]^+$.

Preparation 57

- 5 tert-butyl [2-(4-[(4E)-5-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl}pent-4-en-1-yloxy]phenyl)ethyl]carbamate




- tert-butyl [2-(4-(pent-4-en-1-yloxy)phenyl)ethyl]carbamate (Preparation 56, 1.2g, 3.9mmol), (3R)-3-[2-(benzyloxy)-5-bromophenyl]-N,N-diisopropyl-3-phenylpropan-1-amine (Prepared according to WO9411337, 1.9g, 3.9mmol), palladium acetate (90mg, 0.4mmol), tri(o-tolyl)phosphine (200mg, 0.8mmol), and diisopropylethylamine (1.0ml, 5.9mmol) were mixed in acetonitrile (12ml), degassed with argon and the heated to 90°C for 5 hours. The reaction was cooled to room temperature, filtered through Arbocel and solvent removed *in vacuo*. The residue was taken up in water and ethyl acetate, the organics were separated, dried (magnesium sulphate) and the solvent removed *in vacuo*, the residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (98/2/0.2 to 95/5/5 by volume) to furnish the title compound as a pale yellow foam, 2.5g.

LRMS: m/z 705 $[M+H]^+$.

Preparation 58

- 20 tert-butyl [2-(4-[(5-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}pentyloxy)phenyl]ethyl]carbamate




- Tert-butyl [2-(4-[(4E)-5-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl}pent-4-en-1-yloxy]phenyl)ethyl]carbamate (Preparation 57, 2.5g, 3.5 mmol) was dissolved in ethanol (50ml) and palladium hydroxide (20% by weight on carbon, 600mg, 0.84mmol) and ammonium formate (2.0g, 30mmol) were added and stirred at 90°C for 1 hour. Reaction was cooled and

filtered through arbolcel and the solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (95/5/0.5 to 90/10/1 by volume) to furnish the title compound as a white foam, 1.66g
LRMS: m/z 617 [M+H]⁺.

5

Preparation 59


4-{5-[4-(2-aminoethyl)phenoxy]pentyl}-2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenol bis hydrochloride salt



- 10 Tert-butyl (2-{4-[(5-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}pentyl)oxy]phenyl}ethyl)carbamate (Preparation 58, 1.66g, 2.69mmol) was dissolved in dichloromethane (20ml) and ethanol (3ml) and hydrochloric acid (12ml of a 2M solution in diethyl ether) was added, and the mixture stirred overnight at room temperature. Solvent was removed *in vacuo* and the residue dissolved in dichloromethane and solvent removed *in vacuo* again to furnish the
15 title compound as a yellow foam, 1.6g
LRMS: m/z 517 [M+H]⁺.

Preparation 60

- 20 N-[2-(benzyloxy)-5-{(1R)-1-[(tert-butyl(dimethyl)silyl]oxy}-2-[(2-{4-[(5-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}pentyl)oxy]phenyl}ethyl)amino]ethyl]phenyl]methanesulfonamide



- 4-{5-[4-(2-aminoethyl)phenoxy]pentyl}-2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenol bis hydrochloride salt (Preparation 59, 400mg, 0.68mmol) was dissolved in water and basified with saturated aqueous sodium hydrogen carbonate, then extracted with dichloromethane. Organics were dried (magnesium sulphate) and solvent removed *in vacuo*. The residue was dissolved in dimethylsulfoxide (0.3ml) and N-[2-(benzyloxy)-5-{(1R)-2-bromo-1-[(tert-butyl(dimethyl)silyl]oxy]ethyl]phenyl]methanesulfonamide (Prepared according to WO2005/080324, 400mg, 0.8mmol) added, and heated in a sealed vessel at 80°C for 6 hours.


25

After cooling to room temperature, water was added, extracted with dichloromethane, dried (magnesium sulphate) and solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (95/5/0.5 by volume) to furnish the title compound, 370mg.

- 5 LRMS: m/z 948 $[M+H]^+$.

Preparation 61

N-(5-{(1R)-1-[[tert-butyl(dimethyl)silyl]oxy}-2-[(2-{4-[(5-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}pentyl)oxy]phenyl}ethyl)amino]ethyl)-2-hydroxyphenyl]methanesulfonamide



10


N-[2-(benzyloxy)-5-{(1R)-1-[[tert-butyl(dimethyl)silyl]oxy}-2-[(2-{4-[(5-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}pentyl)oxy]phenyl}ethyl)amino]ethyl

- 15 phenyl]methanesulfonamide (Preparation 60, 350mg, 0.37mmol) was dissolved in ethanol (10ml) and ammonium formate (1.0g, 16mmol) and 20% palladium hydroxide on carbon (250mg) were added and heated to 90°C for 1 hour. Reaction mixture was then cooled and filtered through Arbocel and the solvent removed *in vacuo* to furnish the title compound as a colourless oil, 250mg.

LRMS: m/z 858 $[M+H]^+$.

- 20 Preparation 62

4-{4-[4-(2-{[2-(2R)-2-{4-(benzyloxy)-3-(hydroxymethyl)phenyl]-2-[[tert-butyl(dimethyl)silyl]oxy]ethyl]amino]ethyl]phenoxy]butyl}-2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenol




25

- 4-{4-[4-(2-aminoethyl)phenoxy]butyl}-2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenol tert-butyl {2-[4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)phenyl]ethyl}carbamate bis hydrochloride salt (Preparation 13, 1.30g, 2.26mmol), was dissolved in a mixture of saturated aqueous sodium hydrogen carbonate and
- 5 dichloromethane. The organic layer was separated, dried (magnesium sulphate) and the solvent removed *in vacuo*. The residue was dissolved in acetonitrile (10ml) and {2-(benzyloxy)-5-[(1R)-2-bromo-1-[(tert-butyl(dimethyl)silyl]oxy]ethyl]phenyl}methanol (Prepared according to WO2004/032921, 1.02mg, 2.26mmol), sodium hydrogen carbonate (570mg, 6.78mmol) were added, and heated to 85°C and stirred overnight. After cooling the solvent was removed *in*
- 10 *vacuo* and the residue was dissolved in dichloromethane (30ml) and washed with water (2x20ml) then brine (20ml), dried (magnesium sulphate) and the solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (95/5/1 to 90/10/1 by volume) to furnish the title compound as a gum, 388mg.
- 15 LRMS: m/z 874 [M+H]⁺.

Preparation 63

4-[(1R)-1-[(tert-butyl(dimethyl)silyl]oxy)-2-({2-[4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)phenyl]ethyl}amino)ethyl]-2-(hydroxymethyl)phenol




20

- 4-{4-[4-(2-[(2R)-2-[4-(benzyloxy)-3-(hydroxymethyl)phenyl]-2-[(tert-butyl(dimethyl)silyl]oxy)ethyl]amino)ethyl]phenoxy]butyl}-2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenol (Preparation 62, 388mg, 0.44mmol) was dissolved in ethanol (5ml) and ammonium formate (280mg, 4.44mmol) and 20% palladium hydroxide on carbon (58mg) added.
- 25 The stirred reaction was heated at 85°C for 18 hours. After cooling to room temperature, further ammonium formate (140mg, 2.22mmol) and 20% palladium hydroxide on carbon (20mg) were added and mixture stirred at 85°C for 3 hours. Reaction mixture was then cooled and filtered through Arbocel™, the filtrate was collected and the solvent removed *in vacuo* to furnish the title compound as a glass, 311mg.
- 30 LRMS: m/z 784 [M+H]⁺.

Preparation 64

tert-butyl {2-[4-(2-[4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl]ethoxy)phenyl]-11-dimethylethyl}carbamate



5


tert-butyl [2-(4-hydroxyphenyl)-1,1-dimethylethyl]carbamate (Prepared according to WO1997/34905, 1.5g, 5.6mmol), caesium carbonate (2.9g, 9.0mmol), sodium iodide (670mg, 4.5mmol) and 2-[4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl]ethyl methanesulfonate (Preparation 36, 2.4g, 4.5mmol) were mixed in toluene (18ml) and stirred at 10 120°C overnight. After cooling, water (100ml) and ethyl acetate (100ml) were added, the aqueous layer was then separated and extracted with further ethyl acetate (100ml x 2). The combined organics were then dried (magnesium sulphate) and the solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (95/5/1 by volume) the appropriate fractions were isolated and the solvent removed *in* 15 *vacuo*. The residue was dissolved in minimum volume of ethyl acetate and pentane (100ml) was added. The organics were then washed with aqueous NaOH (1N, 150ml x 2) then dried (magnesium sulphate) and the solvent removed *in vacuo* to yield the title compound as an oil, 1.72g.

LRMS: m/z 694 [M+H]⁺.

20

Preparation 65

(3R)-3-[5-{2-[4-(2-amino-2-methylpropyl)phenoxy]ethyl}-2-(benzyloxy)phenyl]-NN-diisopropyl-3-phenylpropan-1-amine bis hydrochloride salt




25 tert-butyl {2-[4-(2-[4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl]ethoxy)phenyl]-11-dimethylethyl}carbamate (Preparation 64, 1.72g, 2.48mmol) was treated with hydrochloric acid (4M in dioxan, 15ml). After stirring over night at room temperature the solvent was removed *in vacuo* to yield the title compound as a colourless foam, 1.60g

LRMS: m/z 594 [M+H]⁺.

Preparation 66

8-(benzyloxy)-5-[(1R)-2-[(2-[4-(2-(4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl]ethoxy)phenyl]-11-dimethylethyl)amino)-1-[(tert-butyl(dimethyl)silyl]oxy)ethyl]quinolin-2(1H)-one




- (3R)-3-[5-{2-[4-(2-amino-2-methylpropyl)phenoxy]ethyl}-2-(benzyloxy)phenyl]-NN-diisopropyl-3-phenylpropan-1-amine bis hydrochloride salt (Preparation 65, 550mg, 0.83mmol), 8-(benzyloxy)-5-[(1R)-2-bromo-1-[(tert-butyl(dimethyl)silyl]oxy)ethyl]quinolin-2(1H)-one (Prepared according to WO2005/092861, 405mg, 0.83mmol) and sodium hydrogen carbonate (244mg, 2.9mmol) were added to acetonitrile (6ml) and stirred at 90°C under nitrogen for 20 hours. The mixture was cooled and the solvent removed *in vacuo*. The residue was then partitioned between water (40ml) and dichloromethane (40ml), the layers separated and the aqueous layer extracted with further dichloromethane (40ml). The combined organics were dried (magnesium sulphate) and the solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (95/5/0.5 to 80/20/2 by volume) to furnish the title compound as a gum, 100mg.

LRMS: m/z 999 [M-H]⁻.

20 Preparation 67

5-[(1R)-1-[(tert-butyl(dimethyl)silyl]oxy)-2-[(2-[4-(2-[3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]ethoxy)phenyl]-11-dimethylethyl)amino)ethyl]-8-hydroxyquinolin-2(1H)-one




- 8-(benzyloxy)-5-[(1R)-2-[(2-[4-(2-(4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl]ethoxy)phenyl]-11-dimethylethyl)amino)-1-[(tert-butyl(dimethyl)silyl]oxy)ethyl]quinolin-2(1H)-one (Preparation 66, 370mg, 0.37mmol), ammonium

- formate (234mg, 3.7mmol) and 20% palladium hydroxide on carbon (100mg) were mixed in ethanol (5ml) and heated to 85°C, under a nitrogen atmosphere, overnight. Reaction mixture was then cooled and filtered through Celite™ and the filtrate solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (97.5/2.5/0.25 to 95/5/0.5 by volume) to furnish the title compound as a gum, 160mg.
- LRMS: m/z 821 [M+H]⁺.

Example 1


- 10 N-(5-((1R)-2-((10-(3-((1R)-3-(diisopropylamino)-1-phenylpropyl)-4-hydroxyphenyl)decyl)amino)-1-hydroxyethyl)-2-hydroxyphenyl)methanesulfonamide



- Palladium hydroxide (10% on carbon, 20mg) was added to a stirred solution of ammonium formate (344mg, 5.46mmol) and N-{2-(benzyloxy)-5-[(1R)-2-[(10-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl}dec-9-en-1-yl)amino]-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]phenyl)methanesulfonamide (Preparation 4, 90mg; 0.091mmol) in methanol (10ml) at room temperature. The reaction was heated under reflux for 1 hour, cooled to room temperature and filtered through Arbocel™. The filtrate was collected and the solvent removed *in vacuo* to yield
- 15 N-(5-((1R)-1-[[tert-butyl(dimethyl)silyl]oxy]-2-[(10-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}decyl)amino]ethyl)-2-hydroxyphenyl) methanesulfonamide as a mixture with residual ammonium formate. LRMS: m/z 811 [M+H]⁺. This mixture was dissolved in tetrahydrofuran (4ml) and methanol (2ml) and triethylaminetrihydrofluoride (88ul, 0.54mmol) was added in one portion at room temperature. The reaction was stirred for 12 hours and the solvent removed under reduced pressure, the residue was dissolved in methanol (10ml) and 880 ammonia (1ml) and the solvent removed under reduced pressure. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (80/20/2.0 by volume) to furnish the title compound as a glass, 35mg.
- 25 LRMS: m/z 697 [M+H]⁺.

30 Example 2

N-{5-[(1R)-2-[(2-{4-(3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl)propoxy]phenyl)ethyl]amino)-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide




N-{5-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]-2-[(2-[4-(3-{[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}propoxy)phenyl]ethyl]amino)ethyl]-2-hydroxyphenyl]methanesulfonamide (Preparation 10, 98mg, 0.11mmol) was dissolved in tetrahydrofuran (4ml) and methanol (2ml) and triethylaminetrihydrofluoride (95ul, 0.58mmol) was added in one portion at room temperature. The reaction was stirred for 24 hours and the solvent removed under reduced pressure, the residue was dissolved in methanol (10ml) and 880 ammonia (1ml) and the solvent removed under reduced pressure to yield an off white solid. The solid was dissolved in methanol (1ml) and precipitated with an excess of diisopropylether, the solid was collected by filtration to furnish the title compound as a white solid, 16mg.

LRMS: m/z 718 [M+H]⁺.

Example 3

15 N-(5-[(1R)-2-({2-[4-(4-{3-[(1R)-3-(Diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)




N-{5-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]-2-[(2-[4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]butoxy)phenyl]ethyl]amino)ethyl]-2-hydroxyphenyl}methanesulfonamide (Preparation 15, 190mg, 0.22mmol) was dissolved in tetrahydrofuran (5ml) and N,N-diethylethanamine trihydrofluoride (0.2ml, 1mmol) was added dropwise. After 29 hours a mixture of tetrahydrofuran (5ml) and 880 ammonia (5ml) were added and after 15 minutes brine was added, the organic layer was separated, dried (magnesium sulphate), filtered, the solvents were removed *in vacuo* and the residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (98/2/0.2 to 92/8/0.8 by volume) to furnish the title compound as a white foam, 90mg.

LRMS: m/z 732 $[M+H]^+$.

Example 4


N-(5-((1R)-2-((7-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenoxy}heptyl)amino)-
30 1-hydroxyethyl)-2-hydroxyphenyl)methanesulfonamide



- N-(5-((1R)-1-((tert-butyl(dimethyl)silyl)oxy)-2-((7-(3-((1R)-3-(diisopropylamino)-1-phenylpropyl)-4-hydroxyphenoxy)heptyl)amino)ethyl)-2-hydroxyphenyl)methanesulfonamide (Preparation 20, 68mg, 0.087mmol) was dissolved in tetrahydrofuran (3ml) and N,N-diethylethanamine trihydrofluoride (71μl, 0.43mmol) was added dropwise. After 18 hours a mixture of methanol (4ml) and 880 ammonia (8ml) were added and after 15 minutes the solvent was removed *in vacuo*. The residue was dissolved in dichloromethane and the solvent removed *in vacuo* again and the residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (97/3/0.3 to 88/12/1.2 by volume) to furnish the title compound as a white solid, 30mg.
- LRMS: m/z 670 [M+H]⁺.

Example 5

- N-(5-((1R)-2-((2-[4-(2-(3-((1R)-3-(diisopropylamino)-1-phenylpropyl)-4-hydroxyphenyl)ethoxy)phenyl]ethyl)amino)-1-hydroxyethyl)-2-hydroxyphenyl)methanesulfonamide




- N-(2-(benzyloxy)-5-((1R)-2-((2-[4-(2-(4-(benzyloxy)-3-((1R)-3-(diisopropylamino)-1-phenylpropyl)phenyl]ethoxy)phenyl]ethyl)amino)-1-((tert-butyl(dimethyl)silyl)oxy)ethyl)phenyl)methanesulfonamide (Preparation 22, 78mg, 0.078mmol) was dissolved in ethanol (2ml), ammonium formate (200mg, 3.17mmol) was added, heated to reflux then palladium hydroxide (20% by weight on carbon, 50mg, 0.07mmol) was added and after 30 minutes the reaction was cooled to room temperature and the mixture was filtered through ArbocelTM and the solvent removed *in vacuo*. The residue was dissolved in tetrahydrofuran (2ml) and N,N-diethylethanamine trihydrofluoride (59μl, 0.37mmol) was added and after 1 drop of methanol was added and the reaction mixture was stirred over night. The solvent was removed *in vacuo* and the residue dissolved in 1:1 methanol/880 ammonia, the solvents removed *in vacuo* and this process was repeated 4 times. The residue was purified by

column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (230/20/2 to 90/10/1 by volume) to furnish the title compound as a white solid, 28mg.

LRMS: m/z 704 $[M+H]^+$.

5 Example 6

N-{5-[(1R)-2-[[6-(4-{3-[(1R)-3-(Diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]butoxy}hexyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide




- 10 N-{5-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]-2-[[6-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]butoxy}hexyl)amino]ethyl]-2-hydroxyphenyl}methanesulfonamide (Preparation 28, 420mg, 0.51mmol) was dissolved in tetrahydrofuran (6ml) and triethylaminetrihydrofluoride (415ul, 2.55mmol) was added. The reaction was stirred at room temperature for 4 hours and the solvent removed *in vacuo*, the residue was dissolved in methanol (1ml) and 880 ammonia (1ml) and the solvent removed *in vacuo*, the residue was
- 15 dissolved in methanol (1ml) and 880 ammonia (1ml) and the solvent removed *in vacuo*. The resulting oil was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (89/11/1.1 by volume) to furnish the title compound as a yellow solid, 26mg.

LRMS (ES) : m/z 712 $[M+H]^+$.

20

Example 7

N-{5-[(1R)-2-[(2-[4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]butoxy}phenyl)ethyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl}formamide




- 25 N-{5-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]-2-[(2-[4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]butoxy}phenyl)ethyl)amino]ethyl]-2-hydroxyphenyl}formamide (Preparation 30, 280mg, 0.35mmol) was dissolved in tetrahydrofuran (5ml) and triethylaminetrihydrofluoride (0.29ml, 1.8mmol) was added, and the mixture stirred overnight at room temperature. Tetrahydrofuran (6ml) and 880 ammonia (6ml) were then added, the mixture

- stirred for 20 minutes, organics were then separated and washed with saturated aqueous sodium hydrogen carbonate (10ml), then brine (10ml), then dried (magnesium sulphate) and the solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (98/2/0.2 to 88/12/1.2 by volume) to furnish the title compound as an off-white solid, 74mg.
- LRMS: m/z 683 [M+H]⁺.

Example 8


- 5-[(1R)-2-({2-[4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)phenyl]ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one



- 5-[(1R)-1-{{tert-butyl(dimethyl)silyl}oxy}-2-({2-[4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)phenyl]ethyl}amino)ethyl]-8-hydroxyquinolin-2(1H)-one (Preparation 32, 305mg, 0.37mmol) was dissolved in tetrahydrofuran (5ml) and triethylaminetrihydrofluoride (0.30ml, 1.9mmol) was added, and the mixture stirred overnight at room temperature. Tetrahydrofuran (6ml) and 880 ammonia (6ml) were then added, the mixture stirred for 20 minutes, organics were then separated and washed with saturated aqueous sodium hydrogen carbonate (10ml), then brine (10ml), then dried (magnesium sulphate) and the solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (98/2/0.2 to 88/12/1.2 by volume) to furnish the title compound as a yellow solid, 99mg.
- LRMS: m/z 707 [M+H]⁺.

Example 9


- 5-[(1R)-1-{{hydroxy}-2-({2-[4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)phenyl]ethyl}amino)ethyl]benzene-1,3-diol



- 5-[(1R)-1-[(tert-butyl(dimethyl)silyl]oxy]-2-[(2-[4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]butoxy)phenyl]ethyl]amino)ethyl]benzene-1,3-diol (Preparation 34, 555mg, 0.72mmol) was dissolved in tetrahydrofuran (8ml) and triethylaminetrihydrofluoride (0.59ml, 3.6mmol) was added, and the mixture stirred overnight at room temperature. Tetrahydrofuran (6ml) and 880 ammonia (6ml) were then added, the mixture stirred for 20 minutes, organics were then separated and washed with saturated aqueous sodium hydrogen carbonate (10ml), then brine (10ml), then dried (magnesium sulphate) and the solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (98/2/0.2 to 88/12/1.2 by volume) to furnish the title compound as a white solid, 54mg.
- LRMS: m/z 655 [M+H]⁺.

Example 10


- N-[5-[(1R)-2-[(2-[3-(2-[3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]ethoxy)phenyl]ethyl]amino)-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide



- N-[2-(benzyloxy)-5-[(1R)-2-[(2-[3-(2-[4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl]ethoxy)phenyl]ethyl]amino)-1-[(tert-butyl(dimethyl)silyl]oxy)ethyl]phenyl]methanesulfonamide (Preparation 39, 257mg, 0.26mmol) was dissolved in ethanol (20ml) and ammonium formate (325mg, 5.15mmol) and 20% palladium hydroxide on carbon (36mg) were added. The stirred reaction was heated at 90°C, after 2 hours further ammonium formate (325mg, 5.15mmol) and 20% palladium hydroxide on carbon (36mg) were added and mixture stirred at 90°C for further 2 hours. After cooling to room temperature, mixture was filtered and solvent removed *in vacuo*, ethanol (20ml), ammonium formate (325mg, 5.15mmol) and 20% palladium hydroxide on carbon (36mg) were then added, and the mixture heated to 90°C for a further 2 hours. After cooling, the mixture was filtered and solvent removed *in vacuo*. The residue was dissolved in methanol (10ml) and tetrahydrofuran (20ml), and triethylaminetrihydrofluoride (0.25ml, 1.5mmol) added. The mixture was stirred overnight and then the solvent removed *in vacuo*. The residue was dissolved in methanol (10ml) and 880 ammonia (1ml) and the solvent removed under reduced pressure. This was repeated and the residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (99/1/0.1 to 80/20/2.0 by volume) to furnish, following trituration in diisopropyl ether, the title compound as a white solid, 52mg.
- LRMS: m/z 704 [M+H]⁺.

Example 11

2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-(2-{3-[2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)ethyl]phenoxy}ethyl)phenol



5

{2-(benzyloxy)-5-[(1R)-2-[(2-[3-(2-{4-(benzyloxy)-3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl]ethoxy)phenyl]ethyl]amino)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]phenyl]methanol (Preparation 40, 450mg, 0.48mmol), ammonium formate (610mg, 9.6mmol) and 20% palladium hydroxide on carbon (68mg) were stirred in ethanol at 90°C for 30 minutes. Further ammonium formate (610mg, 9.6mmol) and 20% palladium hydroxide on carbon (70mg) were added and mixture stirred at 90°C for further 30 minutes. Mixture cooled to room temperature and stirred overnight, then further ammonium formate (610mg, 9.6mmol) and 20% palladium hydroxide on carbon (70mg) were added, before stirring at 90°C for 1 hour. After cooling, the mixture was filtered and solvent removed *in vacuo*. Methanol (10ml), tetrahydrofuran (20ml) and triethylaminetrihydrofluoride (0.47ml, 2.9mmol) were added and mixture stirred for 3 days at room temperature. The solvent was removed *in vacuo* and the residue was dissolved in methanol (10ml) and 880 ammonia (1ml) and the solvent removed under reduced pressure. This was repeated and the residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (99/1/0.1 to 80/20/2.0 by volume) to furnish, following trituration with diisopropyl ether, the title compound as a white solid, 95mg. LRMS: m/z 641 $[M+H]^+$.

10


15

20

Example 12

5-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]-2-[(2-[4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]ethoxy)phenyl]ethyl]amino)ethyl]benzene-1,3-diol

25




5-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]-2-[(2-[4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]ethoxy)phenyl]ethyl]amino)ethyl]benzene-1,3-diol (Preparation 44, 174mg, 0.23mmol) was dissolved in methanol (5ml) and tetrahydrofuran (10ml), and triethylaminetrihydrofluoride (0.23ml, 1.4mmol) added. The mixture was stirred overnight and

30

then the solvent removed *in vacuo*. The residue was dissolved in methanol (10ml) and 880 ammonia (1ml) and the solvent removed under reduced pressure. This was repeated and the residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (95/5/0.5 to 80/20/2.0 by volume) to furnish the title compound as a foam, 83mg.
LRMS: m/z 627 $[M+H]^+$.

Example 13


N-{5-[(1R)-2-[(2-[4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl)ethoxy]phenyl]ethyl]amino)-1-hydroxyethyl]-2-hydroxyphenyl}formamide



N-{5-[(1R)-1-[(tert-butyl(dimethyl)silyl]oxy]-2-[(2-[4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl)ethoxy]phenyl]ethyl]amino)ethyl]-2-hydroxyphenyl}formamide (Preparation 46, 180mg, 0.18mmol) was dissolved in methanol (5ml) and tetrahydrofuran (10ml), and triethylaminetrihydrofluoride (0.18ml, 1.1mmol) added. The mixture was stirred overnight and then the solvent removed *in vacuo*. The residue was dissolved in methanol (10ml) and 880 ammonia (1ml) and the solvent removed under reduced pressure. This was repeated and the residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (98/2/0.2 to 80/20/2.0 by volume) to furnish the title compound as a gum, 69mg.
LRMS: m/z 654 $[M+H]^+$.

Example 14

5-[(1R)-2-[(2-[4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl)ethoxy]phenyl]ethyl]amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one




8-(benzyloxy)-5-[(1R)-2-[(2-[4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]phenyl]ethoxy]phenyl]ethyl]amino)-1-[(tert-butyl(dimethyl)silyl]oxy)ethyl]quinolin-2(1H)-one (Preparation 47, 295mg, 0.30mmol) was dissolved in methanol (30ml) and ammonium formate (380mg, 6.1mmol) and 20% palladium hydroxide on carbon (43mg) added.

The stirred reaction was then heated at 90°C for 2 hours. After cooling to room temperature, mixture was filtered and solvent removed *in vacuo*. The residue was then taken up in ethyl acetate (50ml) and saturated aqueous sodium hydrogen carbonate (50ml). The organics were separated, washed with brine then dried (magnesium sulphate) and the solvent removed *in vacuo*. The residue was then dissolved in methanol (10ml) and tetrahydrofuran (20ml), and triethylaminetrihydrofluoride (0.30ml, 1.8mmol) added. The mixture was stirred overnight and then the solvent removed *in vacuo*. The residue was dissolved in methanol (20ml) and 880 ammonia (2ml) and the solvent removed under reduced pressure. This was repeated and the residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (98/2/0.2 to 80/20/2.0 by volume) to furnish the title compound as a yellowish foam, 137mg.

LRMS: m/z 678 [M+H]⁺.

Example 15

2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-(2-{4-[2-{(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)ethyl]phenoxy}ethyl)phenol




4-[(1R)-1-[(tert-butyl(dimethyl)silyl]oxy)-2-({2-[4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]ethoxy)phenyl]ethyl]amino)ethyl]-2-(hydroxymethyl)phenol (Preparation 49, 235mg, 0.30 mmol) was dissolved in methanol (2.9ml) and water (1.4ml) and ammonium fluoride (112mg, 3.0mmol) was added. The reaction was heated to 40°C and stirred overnight, cooled to room temperature and then saturated aqueous sodium hydrogen carbonate (20ml) and ethyl acetate (20ml) were added. The aqueous was separated and extracted with ethyl acetate and the combined organics dried (magnesium sulphate) and the solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (80/20/1.0 by volume) to furnish the title compound as a glass, 55mg.

LRMS: m/z 641 [M+H]⁺.

Example 16

N-(5-[(1R)-2-[(8-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]octyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl)methanesulfonamide




N-(5-((1R)-1-((tert-butyl(dimethyl)silyl)oxy)-2-((8-((3-((1R)-3-(diisopropylamino)-1-phenylpropyl)-4-hydroxyphenyl)octyl)amino)ethyl)-2-hydroxyphenyl)methanesulfonamide (Preparation 55, 74mg, 0.095mmol) was dissolved in tetrahydrofuran (3ml) and triethylaminetrihydrofluoride (90ul, 0.54mmol) was added in one portion at room temperature. The reaction was stirred for 12 hours and the solvent removed under reduced pressure, the residue was dissolved in methanol (10ml) and 880 ammonia (1ml) and the solvent removed under reduced pressure. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (97/3/0.3 to 85/15/1.5 by volume) to furnish the title compound as a yellow solid, 34mg.

LRMS: m/z 668 [M+H]⁺.

Example 17

N-(5-((1R)-2-((2-((4-((5-((3-((1R)-3-(diisopropylamino)-1-phenylpropyl)-4-hydroxyphenyl)pentyl)oxy)phenyl)ethyl)amino)-1-hydroxyethyl)-2-hydroxyphenyl)methanesulfonamide




N-(5-((1R)-1-((tert-butyl(dimethyl)silyl)oxy)-2-((2-((4-((5-((3-((1R)-3-(diisopropylamino)-1-phenylpropyl)-4-hydroxyphenyl)pentyl)oxy)phenyl)ethyl)amino)ethyl)-2-hydroxyphenyl)methanesulfonamide (Preparation 61, 250mg, 0.29 mmol) was dissolved in tetrahydrofuran (10ml) and methanol (0.5ml) and triethylaminetrihydrofluoride (1.0ml, 6.1mmol) was added. The reaction was stirred for 3 days and the solvent removed *in vacuo*. The residue was dissolved in 880 ammonia (1ml) and the solvent removed under reduced pressure, this was repeated 3 times. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (95/5/0.5 by volume) to furnish the title compound as a pale yellow foam, 100mg.

LRMS: m/z 746 [M+H]⁺.

Example 18


2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-{4-[2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethoxy]butyl}phenol



- 4-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]-2-[(2-[4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]butoxy)phenyl]ethyl]amino)ethyl]-2-(hydroxymethyl)phenol (Preparation 63, 311mg, 0.356mmol) was dissolved in methanol (4ml) and water (0.5ml) and ammonium fluoride (132mg, 3.56mmol) was added. The reaction was heated to 40°C and stirred overnight. Reaction mixture was cooled and solvent removed *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (100/0/0 to 90/10/1.0 by volume) to furnish the title compound as a glass, 84mg.
- LRMS: m/z 669 $[M+H]^+$.

Example 19


- N-{5-[(1R)-2-[(2-[4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]ethoxy)phenyl]ethyl]amino)-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide succinate salt



- N-{5-[(1R)-2-[(2-[4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]ethoxy)phenyl]ethyl]amino)-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide (Example 5, 2000mg, 2.84mmol) was dissolved in methanol (8ml) and succinic acid (336mg, 2.84mmol) in water (2ml) and methanol (2ml) was added in one portion to the stirred solution at room temperature. Further water was added until the salt appeared as a gum which was seeded with a small crystal of the salt previously isolated. The mixture was left overnight and stirred occasionally to aid crystallisation. After 5 days the solid was filtered and dried *in vacuo* to furnish the title compound as a white crystalline solid, 2336mg, m.p. 148-150°C.
- LRMS: m/z 704 $[M+H]^+$.

Example 20

5-[(1R)-2-({2-[4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}ethoxy)phenyl]-11-dimethylethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one



5-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]-2-({2-[4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}ethoxy)phenyl]-11-dimethylethyl}amino)ethyl]-8-hydroxyquinolin-2(1H)-one (Preparation 67, 160mg, 0.20mmol) was dissolved in methanol (20ml) and water (10ml) and ammonium fluoride (740mg, 3.6mmol) was added. The reaction was heated to 40°C and stirred, under a nitrogen atmosphere, for 21 hours. Reaction mixture was cooled and solvent removed *in vacuo*. The residue azetroped from toluene then dichloromethane to give a white solid which was purified by column chromatography on silica gel eluting with dichloromethane:methanol:880 ammonia (90/10/1 to 80/20/2 by volume) to furnish the title compound as a glass, 19mg. LRMS: m/z 707 [M+H]⁺.

Functional assessment of antagonist activity using a whole Cell β -lactamase reporter assay in CHO cells expressing the hM₃ receptor.

Cell culture

CHO (Chinese Hamster Ovary) cells recombinantly expressing the human muscarinic M₃ receptor were transfected with the NFAT- β -Lac-Zeo plasmid. Cells were grown in DMEM with Glutamax-1, supplemented with 25mM HEPES(Life Technologies 32430-027), containing 10% FCS (Foetal Calf Serum; Sigma F-7524), 1nM Sodium pyruvate (Sigma S-8636), NEAA (non-Essential Amino Acids; Invitrogen 11140-035) and 200 μ g/ml Zeocin (Invitrogen R250-01).

hM₃ β -Lac Assay Protocol

Cells were harvested for assay when they reached 80-90% confluency using enzyme free cell Dissociation Solution (Life technologies 13151-014) incubated with the cells for 5 min at 37°C in an atmosphere containing 5% CO₂. Detached cells were collected in warmed growth media and centrifuged at 2000rpm for 10min, washed in PBS (Phosphate Buffered Saline; Life Technologies 14190-094) and centrifuged again as just described. The cells were re-suspended at 2x10⁵ cells/ml in growth medium (composition as described above). 20 μ l of this cell

suspension was added to each well of a 384 well black clear bottomed plate (Greiner Bio One 781091-PFI). The assay buffer used was PBS supplemented with 0.05% Pluronic F-127 (Sigma 9003-11-6) and 2.5% DMSO. Muscarinic M₃ receptor signalling was stimulated using 80nM carbamyl choline (Aldrich N240-9) incubated with the cells for 4h at 37°C /5% CO₂ and
5 monitored at the end of the incubation period using a Tecan SpectraFluor+ plate reader (λ - excitation 405nm, emission 450nm and 503nm). Compounds under test were added to the assay at the beginning of the 4h incubation period and compound activity measured as the concentration dependent inhibition of the carbamyl choline induced signal. Inhibition curves were plotted and IC₅₀ values generated using a 4-parameter sigmoid fit and converted to Ki
10 values using the Cheng-Prusoff correction and the K_D value for carbamyl choline in the assay.

Functional assessment of agonist potency and efficacy using a whole cell Luciferase reporter assay in CHO cells expressing the hB₂ receptor.

15 **Cell Culture**

CHO (Chinese Hamster Ovary) cells recombinantly expressing the human adrenergic B₂ receptor and transfected with a luciferase enzyme reporter gene were maintained in growth media composed of F12:DMEM (Sigma D6421) containing 10% Foetal Bovine Serum (FBS: Sigma F03921) 10 μ g/ml puromycin (Sigma N277698), 0.5mg/ml Geneticin G418 (Sigma G7034)
20 and 2mM L-glutamine (Sigma G7513). The cells were kept in sterile conditions at 37°C, in an atmosphere containing 5%CO₂.

hB₂ Luciferase Assay Protocol

25

Cells were harvested for assay when they reached 80-90% confluency using enzyme free cell Dissociation Solution (Life technologies 13151-014) incubated with the cells for 5 min at 37°C in an atmosphere containing 5% CO₂. Detached cells were collected in warmed growth media (composition described above), and re-suspended in assay media (F12:DMEM (Sigma D6421)
30 containing 1% Foetal Bovine Serum (FBS: Sigma F03921), 10 μ g/ml puromycin (Sigma N277698), 0.5mg/ml Geneticin G418 (Sigma G7034) and 2mM L-glutamine (Sigma G7513))to give a viable cell concentration of 1x10⁶ cells/ml. 10 μ l of this suspension was added to each well of a tissue culture treated low volume 384 well plate (Greiner788073) and the plate incubated in an atmosphere containing 5% CO₂ at 37°C for 2h. Concentration ranges of test
35 compounds were prepared in phosphate Buffered Saline containing 0.05% pluronic-F127 (Sigma P2443) and 2.5% DMSO. 2 μ l of each test concentration were added to the appropriate 384 plate well and returned to the incubator for a further 4h. At the end of the incubation period 4 μ l of Steady-Glo reagent (Steady-Glo Luciferase assay system (Promega E2520) was added to

each well and the plate read immediately in a Leadseeker Plate reader (Amersham Bioscience) using a 660nm filter. Concentration effect curves were plotted and EC₅₀ values generated using a 4-parameter sigmoid fit using an in-house data analysis programme. Isoprenaline was run in every assay as a reference standard.

5


Examples 1 to 20 were tested according to the here above disclosed assays and the following results were obtained:

Example No.	EC50 – beta2 (nM)	Ki – M3 (nM)
1	0.88	3.4
2	0.32	1.1
3	0.14	1.4
4	1.3	0.28
5	0.2	0.3
6	0.19	2.4
7	0.049	2.1
8	0.035	0.31
9	4.8	1.1
10	0.26	1.10
11	2.2	1.5
12	13.8	0.26
13	0.078	0.38
14	0.054	0.76
15	0.25	0.060
16	1.3	2.0
17	0.57	3.0
18	0.22	0.77
19	0.2	0.3
20	0.028	0.39


10

CLAIMS

1. A compound of general formula (1),




wherein A is selected from:



wherein * represent the attachment point of A to the carbon bearing the hydroxy;


and B is selected from:

- 1) $^{**}-(CH_2)_2-(CH_2)_m-X^1-(CH_2)_n-^{***}$ wherein X^1 is O or S, m is an integer from 0 to 9, n is an integer from 0 to 9 and $n+m$ is comprised between 4 to 9 inclusive;
- 2) C_6-C_{12} alkylene optionally substituted with one or two C_1-C_4 alkyl;
- 3) a group of formula



wherein X^2 is O or S, r is an integer from 2 to 7, s is an integer from 0 to 6, t is an integer from 0 to 6, $s+t$ is comprised between 1 to 6 inclusive and $r+s+t$ is comprised between 3 to 8 inclusive; and

- 4) a group of formula:



** representing the attachment point of B to the adjacent NH group and *** representing the attachment point of B to the adjacent phenyl group;

and quaternary ammonium salts thereof or, if appropriate, their pharmaceutically acceptable salts and/or stereoisomers, tautomers or isotopic variations thereof.

2. A compound according to claim 1 wherein B is C_6-C_{12} alkylene.


3. A compound according to claim 2 wherein B is selected from $(CH_2)_8$, $(CH_2)_9$ or $(CH_2)_{10}$.

4. A compound according to claim 1 wherein B is $(\text{CH}_2)_2-(\text{CH}_2)_m-\text{X}^1-(\text{CH}_2)_n$.

5. A compound according to claim 4 wherein X^1 is O.


6. A compound according to claim 5 wherein B is selected from $(\text{CH}_2)_6-\text{O}-(\text{CH}_2)_3$, $(\text{CH}_2)_6-\text{O}-(\text{CH}_2)_4$, and, $(\text{CH}_2)_7-\text{O}-$.

7. A compound according to claim 1 wherein B is a group of formula




8. A compound according to claim 7 wherein X^2 is O.


9. A compound according to claim 8 wherein B is selected from




10. A compound according to claim 9 where B is selected from:




11. A compound according to claim 1 wherein B is of formula:



12. A compound according to claim 11 wherein B is of formula:



13. A compound according to any one of claims 1 to 12 wherein A is of formula:



14. A compound according to claim 1 selected from the group consisting of:

N-{5-[(1R)-2-[(10-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}decyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide;

N-{5-[(1R)-2-[(2-{4-(3-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}propoxy)phenyl]ethyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl}methane sulfonamide;

N-{5-[(1R)-2-[(2-{4-(4-{3-[(1R)-3-(Diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)phenyl]ethyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide;

N-{5-[(1R)-2-[(7-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenoxy}heptyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide;

N-{5-[(1R)-2-[(2-{4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}ethoxy)phenyl]ethyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide;

N-{5-[(1R)-2-[(6-{4-(3-{3-[(1R)-3-(Diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)hexyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide;

N-{5-[(1R)-2-[(2-{4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)phenyl]ethyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl}formamide;

5-[(1R)-2-[(2-{4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)phenyl]ethyl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one;

5-[(1R)-1-[[hydroxy]-2-[(2-{4-(4-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}butoxy)phenyl]ethyl)amino)ethyl]benzene-1,3-diol;

N-{5-[(1R)-2-[(2-{3-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}ethoxy)phenyl]ethyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide;

2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-(2-{3-[2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)ethyl]phenoxy}ethyl)phenol;

5-[(1R)-2-[(2-{4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}ethoxy)phenyl]ethyl)amino]-1-hydroxyethyl]benzene-1,3-diol;

N-{5-[(1R)-2-[(2-{4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}ethoxy)phenyl]ethyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl}formamide;


5-[(1R)-2-[(2-{4-(2-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}ethoxy)phenyl]ethyl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one;

2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-(2-{4-[2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy}ethyl)phenol;
 N-{5-[(1R)-2-[(8-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}octyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide;
 N-{5-[(1R)-2-[(2-{4-[(5-{3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl}pentyl)oxy]phenyl]ethyl]amino)-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide;
 2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-(4-{4-[2-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy}butyl)phenol;
 N-{5-[(1R)-2-[(2-{4-[2-[(3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]ethoxy)phenyl]ethyl]amino)-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide succinate salt;
 5-[(1R)-2-[(2-{4-[2-[(3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]ethoxy)phenyl]-11-dimethylethyl]amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one;
 and quaternary ammonium salts thereof or, if appropriate, their pharmaceutically acceptable salts and/or stereoisomers, tautomers, or isotopic variations thereof.

15. A compound according to claim 1 which is N-{5-[(1R)-2-[(2-{4-[2-[(3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]ethoxy)phenyl]ethyl]amino)-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide and quaternary ammonium salts thereof or, if appropriate, its pharmaceutically acceptable salts and/or stereoisomers, tautomers or isotopic variations thereof.


16. A compound according to claim 15 which is N-{5-[(1R)-2-[(2-{4-[2-[(3-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-hydroxyphenyl]ethoxy)phenyl]ethyl]amino)-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide succinate salt.

17. A quaternary ammonium salt of a compound according to claim 1, said quaternary ammonium salt being of formula:



wherein X is acetate, fumarate, mesylate, bromide, chloride, sulphate, D and L tartrate or xinafoate.

18. A quaternary ammonium salt of a compound according to claim 1, said quaternary ammonium salt being of formula:



wherein X is succinate.

19. A pharmaceutical composition comprising at least an effective amount of a compound of the formula (1) as described in any one of claims 1 to 16 or a pharmaceutically acceptable salt or derived form thereof.

20. A pharmaceutical composition according to claim 19, further comprising one or more pharmaceutically acceptable excipients and/or additives.

21. A compound of the formula (1) as described in any one of claims 1 to 18 or a pharmaceutically acceptable salt, derived form or composition thereof, for use as a medicament.

22. A compound of the formula (1) as described in any one of claims 1 to 18 or a pharmaceutically acceptable salt, derived form or composition thereof, for use in the treatment of diseases, disorders, and conditions in which the β_2 and M3 receptors are involved.

23. A compound of the formula (1) as described in any one of claims 1 to 18 or a pharmaceutically acceptable salt, derived form or composition thereof, for use in the treatment of diseases, disorders, and conditions selected from the group consisting of:

- asthma of whatever type, etiology, or pathogenesis, in particular asthma that is a member selected from the group consisting of atopic asthma, non-atopic asthma, allergic asthma, atopic bronchial IgE-mediated asthma, bronchial asthma, essential asthma, true asthma, intrinsic asthma caused by pathophysiologic disturbances, extrinsic asthma caused by environmental factors, essential asthma of unknown or inapparent cause, non-atopic asthma, bronchitic asthma, emphysematous asthma, exercise-induced asthma, allergen induced asthma, cold air induced asthma, occupational asthma, infective asthma caused by bacterial, fungal, protozoal, or viral infection, non-allergic asthma, incipient asthma, wheezy infant syndrome and bronchiolitis,
- chronic or acute bronchoconstriction, chronic bronchitis, small airways obstruction, and emphysema,
- obstructive or inflammatory airways diseases of whatever type, etiology, or pathogenesis, in particular an obstructive or inflammatory airways disease that is a member selected from the group consisting of chronic eosinophilic pneumonia, chronic obstructive pulmonary disease (COPD), COPD that includes chronic bronchitis, pulmonary emphysema or dyspnea associated or not associated with COPD, COPD that is characterized by irreversible, progressive airways obstruction, adult respiratory distress syndrome (ARDS), exacerbation of airways hyper-reactivity consequent to other drug therapy and airways disease that is associated with pulmonary hypertension,
- bronchitis of whatever type, etiology, or pathogenesis, in particular bronchitis that is a member selected from the group consisting of acute bronchitis, acute laryngotracheal bronchitis,

arachidic bronchitis, catarrhal bronchitis, croupus bronchitis, dry bronchitis, infectious asthmatic bronchitis, productive bronchitis, staphylococcus or streptococcal bronchitis and vesicular bronchitis,

- acute lung injury,
- bronchiectasis of whatever type, etiology, or pathogenesis, in particular bronchiectasis that is a member selected from the group consisting of cylindric bronchiectasis, sacculated bronchiectasis, fusiform bronchiectasis, capillary bronchiectasis, cystic bronchiectasis, dry bronchiectasis and follicular bronchiectasis.





24. The use of a compound of the formula (1) as described in any one of claims 1 to 18 or of a pharmaceutically acceptable salt, solvate or composition thereof, for the manufacture of a drug for the treatment of diseases, disorders, and conditions selected from the group as described in claim 23.

25. Combination of a compound according to any one of claims 1 to 16 with other therapeutic agent(s) selected from:

- (a) 5-Lipoxygenase (5-LO) inhibitors or 5-lipoxygenase activating protein (FLAP) antagonists,
- (b) Leukotriene antagonists (LTRAs) including antagonists of LTB₄, LTC₄, LTD₄, and LTE₄,
- (c) Histamine receptor antagonists including H1 and H3 antagonists,
- (d) α_1 - and α_2 -adrenoceptor agonist vasoconstrictor sympathomimetic agents for decongestant use,
- (e) PDE inhibitors, e.g. PDE3, PDE4 and PDE5 inhibitors,
- (f) Theophylline,
- (g) Sodium cromoglycate,
- (h) COX inhibitors both non-selective and selective COX-1 or COX-2 inhibitors (NSAIDs),
- (i) Prostaglandin receptor antagonists and inhibitors of prostaglandin synthase.
- (j) Oral and inhaled glucocorticosteroids,
- (k) Dissociated agonists of the corticoid receptor (DAGR);
- (l) Monoclonal antibodies active against endogenous inflammatory entities,
- (m) Anti-tumor necrosis factor (anti-TNF- α) agents,
- (n) Adhesion molecule inhibitors including VLA-4 antagonists,
- (o) Kinin-B₁ - and B₂-receptor antagonists,
- (p) Immunosuppressive agents, including inhibitors of the IgE pathway and cyclosporine,
- (q) Inhibitors of matrix metalloproteases (MMPs),
- (r) Tachykinin NK₁, NK₂ and NK₃ receptor antagonists,
- (s) Protease inhibitors such as elastase inhibitors,
- (t) Adenosine A2a receptor agonists and A2b antagonists,
- (u) Inhibitors of urokinase,
- (v) Compounds that act on dopamine receptors, such as D2 agonists,
- (w) Modulators of the NF κ B pathway, such as IKK inhibitors,

- (x) modulators of cytokine signalling pathways such as p38 MAP kinase, PI3 kinase, JAK kinase, syk kinase, EGFR or MK-2,
- (y) Agents that can be classed as mucolytics or anti-tussive,
- (z) Agents, which enhance responses to inhaled corticosteroids.
- (aa) Antibiotics and antiviral agents effective against micro-organisms which can colonise the respiratory tract,
- (bb) HDAC inhibitors,
- (cc) CXCR2 antagonists,
- (dd) Integrin antagonists,
- (ee) Chemokines,
- (ff) Epithelial sodium channel (ENaC) blockers or Epithelial sodium channel (ENaC) inhibitors,
- (gg) P2Y2 Agonists and other Nucleotide receptor agonists,
- (hh) Inhibitors of thromboxane,
- (ii) Niacin, and
- (jj) Adhesion factors including VLAM, ICAM, and ELAM.

26. A compound of formula:



wherein:


B is as defined in claim 1,

Ra represents hydrogen or a benzyl

Rb and Rc represent allyl, benzyl, t-butyl carbamate or phthalimide when joined together,

B² is selected from:

- CH₂-(CH₂)_m-X¹-(CH₂)_{n1} wherein X¹ is O or S, m is an integer from 0 to 9, n₁ is an integer from 1 to 7 and n₁+m is comprised between 2 to 7 inclusive;
- C₃-C₉ alkylene optionally substituted with one or two C₁-C₄ alkyl; or
- a group of formula:



wherein X^2 is O or S, r_1 is an integer from 1 to 6, s is an integer 0 to 6 and t_1 is an integer from 1 to 4 and $s+t_1$ is comprised between 1 to 4 inclusive and r_1+s+t_1 is comprised between 2 to 5 inclusive.